Endeavor Releases First Quarter 2023 Results

Endeavor Releases First Quarter 2023 Results

Announces Plan to Repurchase Shares and Issue First-Ever Quarterly Dividend

BEVERLY HILLS, Calif.–(BUSINESS WIRE)–
Endeavor Group Holdings, Inc. (NYSE: EDR) (“Endeavor”, “EGH”, or the “Company”), a global sports and entertainment company, today released its financial results for the quarterly period ended March 31, 2023.

Highlights

  • Announced two significant transactions in April:

    • Transformational deal to combine UFC and WWE to form a new, publicly listed company

    • Agreement to sell IMG Academy for an enterprise value of $1.25 billion

  • Expect to commence an event-driven share repurchase of up to $300 million of Class A common stock

  • Plan to begin making quarterly cash dividend payments

  • Record Q1 revenue and Adjusted EBITDA for Owned Sports Properties segment

  • Saw heightened demand for events, including record attendance and sponsorship sales at the Miami Open

Q1 2023 Consolidated Financial Results

  • Revenue: $1.597 billion

  • Net income: $36.3 million

  • Adjusted EBITDA: $306.4 million

“This quarter, we continued to deliver solid results and set a number of financial and attendance records across our owned sports properties and marquee events,” said Ariel Emanuel, CEO, Endeavor. “Our agreement to sell IMG Academy, together with the planned share repurchase and quarterly dividend announced today, are strong examples of our commitment to maximizing return for our shareholders. We are excited about the unique opportunity the proposed combination of UFC and WWE presents, and remain focused on durable growth as we continue to execute our successful strategy in content and experiences.”

Segment Operating Results

  • Owned Sports Properties segment revenue was $353.3 million for the quarter, up $56.6 million, or 19.1%, compared to the first quarter of 2022. Growth was primarily driven by an increase in media rights fees, sponsorships, commercial pay-per-view, and event-related revenue at UFC, primarily resulting from an additional Pay-Per-View event in the quarter, as well as more events with live audiences. Segment results also improved on increased ticket sales at PBR and increased revenue from PBR’s new team series. The segment’s Adjusted EBITDA was $185.7 million, up $36.9 million, or 24.8%, year-over-year.
  • Events, Experiences & Rights segment revenue was $800.8 million for the quarter, up $19.9 million, or 2.5%, compared to the first quarter of 2022. Growth was primarily driven by record attendance and sponsorship sales at the Miami Open and growth at IMG Academy, as well as the addition this quarter of Barrett-Jackson, which was acquired in August 2022. Growth was partially offset by the discontinuation of On Location’s music festival business in Mexico, which accounted for $75 million in the prior-year quarter. The segment’s Adjusted EBITDA was $108.0 million for the quarter, down $18.0 million, or 14.3%, year-over-year.
  • Representation segment revenue was $350.2 million for the quarter, down $7.1 million, or 2.0%, compared to the first quarter of 2022. The decrease in segment revenue was primarily attributable to $14 million of revenue recorded in the prior year quarter from the restricted Endeavor Content business, which was sold in January 2022. Segment revenue was also impacted by a decrease at our 160over90 business due to the disposition of certain contracts in the quarter, partially offset by revenue increases at WME. Adjusted EBITDA was $84.2 million for the quarter, down $17.5 million, or 17.2%, year-over-year.
  • Sports Data & Technology segment revenue was $100.9 million, up $55.8 million, or 123.9%, compared to the first quarter of 2022. Growth was driven by the addition of OpenBet, which we acquired in September 2022, as well as growth at IMG ARENA. The segment’s Adjusted EBITDA was $4.5 million for the quarter, down $2.0 million, or 31.0%, year-over-year, which was affected by certain costs at IMG ARENA incurred in advance of the sales cycle.

2023 Full Year Guidance

  • Revenue expected between $5.665 billion and $5.815 billion

  • Adjusted EBITDA expected between $1.220 billion to $1.275 billion

  • Updated guidance primarily reflects expected sale of IMG Academy

Balance Sheet and Liquidity

At March 31, 2023, cash and cash equivalents totaled $718.7 million, compared to $767.8 million at December 31, 2022. Total debt was $5.151 billion at March 31, 2023, compared to $5.169 billion at December 31, 2022. Upon close of the sale of IMG Academy, Endeavor expects to commence repurchases of up to $300 million under an event-driven share repurchase authorization and pay down an additional $50 million of debt. Endeavor also expects to start making quarterly cash dividends of up to $25 million from Endeavor Operating Company to its common unit holders, including EGH, which, in turn, would dividend its portion each quarter to all holders of Endeavor’s Class A common stock. Endeavor expects to declare and pay the first dividend in the third quarter of 2023.

For further information regarding the Company’s financial results, as well as certain non-GAAP financial measures, and the reconciliations thereof, please refer to the following pages of this release or visit the Company’s Investor Relation site at investor.endeavorco.com.

Webcast Details

Endeavor will host an audio webcast to discuss its results and provide a business update at 2 p.m. PT / 5 p.m. ET today. The event can be accessed at: https://events.q4inc.com/attendee/338510069

The link to the webcast, as well as a recording, will also be available within the News/Events section of investor.endeavorco.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the Company’s guidance for full year 2023, its expected long-term value and market position, contemplated debt repayment, repurchases under the share repurchase authorization and the commencement of declaring a quarterly cash dividend. The words “believe,” “may,” “will,” “estimate,” “potential,” “continue,” “anticipate,” “intend,” “expect,” “could,” “would,” “project,” “plan,” “target,” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to: changes in public and consumer tastes and preferences and industry trends; Endeavor’s ability to adapt to or manage new content distribution platforms or changes in consumer behavior; Endeavor’s dependence on the relationships of its management, agents, and other key personnel with clients; Endeavor’s dependence on key relationships with television and cable networks, satellite providers, digital streaming partners, corporate sponsors, and other distribution partners; risks related to Endeavor’s gaming business and applicable regulatory requirements; risks related to Endeavor’s organization and structure; and other important factors discussed in Part I, Item 1A “Risk Factors” in Endeavor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as any such factors may be updated from time to time in the Company’s other filings with the SEC, including without limitation, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, accessible on the SEC’s website at www.sec.gov and Endeavor’s Investor Relations site at investor.endeavorco.com. Forward-looking statements speak only as of the date they are made and, except as may be required under applicable law, Endeavor undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Additional Information Regarding Share Repurchase Authorization and Quarterly Dividend

Repurchases under the share repurchase authorization may be made in the open market, in privately negotiated transactions or otherwise, with the amount and timing of repurchases to be determined at Endeavor’s discretion, depending on market conditions and corporate needs and would be structured to occur in accordance with applicable federal securities laws. This authorization has no expiration and may be modified, suspended or terminated at any time at Endeavor’s discretion. It also does not obligate Endeavor to acquire any particular amount of Class A common stock. In addition, the ultimate amount of each quarterly dividend referenced above will be subject to market conditions and cash flow requirements.

Non-GAAP Financial Measures

We refer to certain financial measures that are not recognized under United States generally accepted accounting principles (“GAAP”). Please see “Note Regarding Non-GAAP Financial Measures” and the reconciliation tables below for additional information and a reconciliation of the Non-GAAP financial measures to the most comparable GAAP financial measures.

About Endeavor

Endeavor is a global sports and entertainment company, home to many of the world’s most dynamic and engaging storytellers, brands, live events and experiences. The company is comprised of industry leaders including entertainment agency WME; sports, fashion, events and media company IMG; and premier mixed martial arts organization UFC. The Endeavor network specializes in talent representation, sports operations & advisory, event & experiences management, media production & distribution, experiential marketing and brand licensing.

Website Disclosure

Investors and others should note that we announce material financial and operational information to our investors using press releases, SEC filings and public conference calls webcasts, as well as our Investor Relations site at investor.endeavorco.com. We may also use our website as a distribution channel of material Company information. In addition, you may automatically receive email alerts and other information about Endeavor when you enroll your email address by visiting the “Investor Email Alerts” option under the Resources tab on investor.endeavorco.com.

 

Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share data)

 

Three Months Ended March 31,

 

2023

 

 

 

2022

 

Revenue

$

1,596,837

 

$

1,473,763

 

Operating expenses:
Direct operating costs

 

724,282

 

 

694,641

 

Selling, general and administrative expenses

 

669,213

 

 

540,206

 

Insurance recoveries

 

 

 

(993

)

Depreciation and amortization

 

66,751

 

 

65,994

 

Total operating expenses

 

1,460,246

 

 

1,299,848

 

Operating income

 

136,591

 

 

173,915

 

Other (expense) income:
Interest expense, net

 

(85,097

)

 

(59,272

)

Tax receivable agreement liability adjustment

 

2,344

 

 

(53,497

)

Other income, net

 

24,433

 

 

459,941

 

Income before income taxes and equity losses of affiliates

 

78,271

 

 

521,087

 

Provision for (benefit from) income taxes

 

35,470

 

 

(17,234

)

Income before equity losses of affiliates

 

42,801

 

 

538,321

 

Equity losses of affiliates, net of tax

 

(6,546

)

 

(20,655

)

Net income

 

36,255

 

 

517,666

 

Less: Net income attributable to non-controlling interests

 

28,224

 

 

198,120

 

Net income attributable to Endeavor Group Holdings, Inc.

$

8,031

 

$

319,546

 

 
 
Earnings per share of Class A common stock:
Basic

$

0.03

 

$

1.19

 

Diluted

$

0.03

 

$

1.16

 

 
Weighted average number of shares used in computing earnings per share:
Basic

 

291,936,777

 

 

268,489,176

 

Diluted(1)

 

295,285,241

 

 

443,038,617

 

 
(1) The diluted weighted average number of shares of 295,285,241 for the three months ended March 31, 2023 includes weighted average Class A common shares outstanding, plus an assumed exchange of Endeavor Profits Units into 714,931 shares of the Company’s Class A common stock and additional shares from Stock Options, RSUs and Phantom Units, as noted in the table below:
 
Weighted average Class A Common Shares outstanding – Basic

 

291,936,777

 

Additional shares assuming exchange of EOC Profits Units

 

714,931

 

Additional shares from RSUs, Stock Options and Phantom Units, as calculated using the treasury stock method

 

2,633,533

 

Weighted average Class A Common Shares outstanding – Diluted

 

295,285,241

 

 
Securities that are anti-dilutive for the three months ended March 31, 2023, are additional shares based on an assumed exchange of Endeavor Manager Units and Endeavor Operating Units into 158,796,941 shares, additional shares based on an assumed exchange of 12,488,885 Endeavor Profits Units, as well as additional shares from Stock Options, RSUs and redeemable non-controlling interests.
 

Segment Results

(Unaudited)

(In thousands)

 

Three Months Ended March 31,

2023

 

2022

Revenue:
Owned Sports Properties

$

353,289

 

$

296,689

 

Events, Experiences & Rights

 

800,786

 

 

780,935

 

Representation

 

350,240

 

 

357,321

 

Sports Data & Technology

 

100,859

 

 

45,043

 

Eliminations

 

(8,337

)

 

(6,225

)

Total Revenue

$

1,596,837

 

$

1,473,763

 

 
Adjusted EBITDA:
Owned Sports Properties

$

185,671

 

$

148,741

 

Events, Experiences & Rights

 

107,991

 

 

126,001

 

Representation

 

84,206

 

 

101,705

 

Sports Data & Technology

 

4,472

 

 

6,482

 

Corporate

 

(75,948

)

 

(68,480

)

 

Consolidated Balance Sheets

(Unaudited)

(In thousands, except share data)

 

March 31,

 

December 31,

 

2023

 

 

 

2022

 

 
ASSETS
Current Assets:
Cash and cash equivalents

$

718,658

 

$

767,828

 

Restricted cash

 

267,605

 

 

278,165

 

Accounts receivable (net of allowance for doubtful accounts of $57,128 and $54,766, respectively)

 

991,618

 

 

917,000

 

Deferred costs

 

283,326

 

 

268,524

 

Assets held for sale

 

5,984

 

 

12,013

 

Other current assets

 

271,018

 

 

293,206

 

Total current assets

 

2,538,209

 

 

2,536,736

 

 
Property and equipment, net

 

711,589

 

 

696,302

 

Operating lease right-of-use assets

 

337,422

 

 

346,550

 

Intangible assets, net

 

2,190,078

 

 

2,205,583

 

Goodwill

 

5,302,070

 

 

5,284,697

 

Investments

 

348,548

 

 

336,973

 

Deferred income taxes

 

804,981

 

 

771,382

 

Other assets

 

386,793

 

 

325,619

 

Total assets

$

12,619,690

 

$

12,503,842

 

 
LIABILITIES, REDEEMABLE INTERESTS AND SHAREHOLDERS’ EQUITY
Current Liabilities:
Accounts payable

$

615,232

 

$

600,605

 

Accrued liabilities

 

531,381

 

 

525,239

 

Current portion of long-term debt

 

88,686

 

 

88,309

 

Current portion of operating lease liabilities

 

68,673

 

 

65,381

 

Deferred revenue

 

730,034

 

 

716,147

 

Deposits received on behalf of clients

 

247,776

 

 

258,414

 

Liabilities held for sale

 

 

 

2,672

 

Current portion of tax receivable agreement liability

 

154,893

 

 

50,098

 

Other current liabilities

 

106,359

 

 

107,675

 

Total current liabilities

 

2,543,034

 

 

2,414,540

 

 
Long-term debt

 

5,062,508

 

 

5,080,237

 

Long-term operating lease liabilities

 

314,556

 

 

327,888

 

Long-term tax receivable agreement liability

 

842,935

 

 

961,623

 

Other long-term liabilities

 

459,693

 

 

412,982

 

Total liabilities

 

9,222,726

 

 

9,197,270

 

 
Commitments and contingencies
 
Redeemable non-controlling interests

 

254,239

 

 

253,079

 

 
Shareholders’ Equity:
Class A common stock, $0.00001 par value; 5,000,000,000 shares authorized; 299,352,355 and 290,541,729 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively

 

2

 

 

2

 

Class B common stock, $0.00001 par value; 5,000,000,000 shares authorized; none issued and outstanding as of March 31, 2023 and December 31, 2022

 

 

 

 

Class C common stock, $0.00001 par value; 5,000,000,000 shares authorized; none issued and outstanding as of March 31, 2023 and December 31, 2022

 

 

 

 

Class X common stock, $0.00001 par value; 4,983,448,411 and 4,987,036,068 shares authorized; 175,912,198 and 182,077,479 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively

 

1

 

 

1

 

Class Y common stock, $0.00001 par value; 989,681,838 and 997,261,325 shares authorized; 227,523,031 and 227,836,134 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively

 

2

 

 

2

 

Additional paid-in capital

 

2,248,015

 

 

2,120,794

 

Accumulated deficit

 

(208,188

)

 

(216,219

)

Accumulated other comprehensive loss

 

(14,997

)

 

(23,736

)

Total Endeavor Group Holdings, Inc. shareholders’ equity

 

2,024,835

 

 

1,880,844

 

Nonredeemable non-controlling interests

 

1,117,890

 

 

1,172,649

 

Total shareholders’ equity

 

3,142,725

 

 

3,053,493

 

Total liabilities, redeemable interests and shareholders’ equity

$

12,619,690

 

$

12,503,842

 

Note Regarding Non-GAAP Financial Measures

This press release includes financial measures that are not calculated in accordance with United States generally accepted accounting principles (“GAAP”), including Adjusted EBITDA and Adjusted EBITDA Margin.

Adjusted EBITDA is a non-GAAP financial measure and is defined as net income (loss), excluding income taxes, net interest expense, depreciation and amortization, equity-based compensation, merger, acquisition and earn-out costs, certain legal costs, restructuring, severance and impairment charges, certain non-cash fair value adjustments, certain equity earnings, tax receivable agreement liability adjustment, and certain other items, when applicable. Adjusted EBITDA margin is a non-GAAP financial measure defined as Adjusted EBITDA divided by Revenue.

Management believes that Adjusted EBITDA is useful to investors as it eliminates the significant level of non-cash depreciation and amortization expense that results from our capital investments and intangible assets recognized in business combinations, and improves comparability by eliminating the significant level of interest expense associated with our debt facilities, as well as income taxes and the tax receivable agreement, which may not be comparable with other companies based on our tax and corporate structure.

Adjusted EBITDA and Adjusted EBITDA margin are used as the primary bases to evaluate our consolidated operating performance.

Adjusted EBITDA, and Adjusted EBITDA margin have limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

  • they do not reflect every cash expenditure, future requirements for capital expenditures, or contractual commitments;

  • Adjusted EBITDA does not reflect the significant interest expense or the cash requirements necessary to service interest or principal payments on our debt;

  • although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced or require improvements in the future, and Adjusted EBITDA and Adjusted EBITDA margin do not reflect any cash requirement for such replacements or improvements; and

  • they are not adjusted for all non-cash income or expense items that are reflected in our statements of cash flows.

We compensate for these limitations by using Adjusted EBITDA and Adjusted EBITDA margin along with other comparative tools, together with GAAP measurements, to assist in the evaluation of operating performance.

Adjusted EBITDA and Adjusted EBITDA margin should not be considered substitutes for the reported results prepared in accordance with GAAP and should not be considered in isolation or as alternatives to net income (loss) as indicators of our financial performance, as measures of discretionary cash available to us to invest in the growth of our business or as measures of cash that will be available to us to meet our obligations. Although we use Adjusted EBITDA and Adjusted EBITDA margin as financial measures to assess the performance of our business, such use is limited because it does not include certain material costs necessary to operate our business. Our presentation of Adjusted EBITDA and Adjusted EBITDA margin should not be construed as indications that our future results will be unaffected by unusual or nonrecurring items. These non-GAAP financial measures, as determined and presented by us, may not be comparable to related or similarly titled measures reported by other companies. Set forth below are reconciliations of our most directly comparable financial measures calculated in accordance with GAAP to these non-GAAP financial measures on a consolidated basis.

A reconciliation of the Company’s Adjusted EBITDA guidance to the most directly comparable GAAP financial measure cannot be provided without unreasonable efforts and is not provided herein because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including income taxes, equity-based compensation, merger, acquisition and earn-out costs, certain legal costs, restructuring, severance and impairment charges, certain non-cash fair value adjustments, certain equity earnings, tax receivable agreement liability adjustment, and certain other items reflected in our reconciliation of historical Adjusted EBITDA, the amounts of which, could be material.

 

Adjusted EBITDA

(Unaudited)

(In thousands)

 

Three Months Ended March 31,

 

2023

 

 

 

2022

 

Net income

$

36,255

 

$

517,666

 

Provision for (benefit from) income taxes

 

35,470

 

 

(17,234

)

Interest expense, net

 

85,097

 

 

59,272

 

Depreciation and amortization

 

66,751

 

 

65,994

 

Equity-based compensation expense (1)

 

78,691

 

 

50,856

 

Merger, acquisition and earn-out costs (2)

 

14,534

 

 

12,794

 

Certain legal costs (3)

 

2,422

 

 

1,002

 

Restructuring, severance and impairment (4)

 

8,200

 

 

518

 

Fair value adjustment – equity investments (5)

 

(713

)

 

(1,653

)

Equity method losses – Learfield IMG College and Endeavor Content (6)

 

8,523

 

 

24,404

 

Gain on sale of the restricted Endeavor Content business (7)

 

 

 

(463,641

)

Tax receivable agreement liability adjustment (8)

 

(2,344

)

 

53,497

 

Other (9)

 

(26,494

)

 

10,974

 

Adjusted EBITDA

$

306,392

 

$

314,449

 

Net income margin

 

2.3

%

 

35.1

%

Adjusted EBITDA margin

 

19.2

%

 

21.3

%

_________

(1)

 

Equity-based compensation represents primarily non-cash compensation expense associated with our equity-based compensation plans.

 

 

The increase for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022 was primarily due to grants issued under the Endeavor Group Holdings, Inc.’s 2021 Incentive Award Plan during the three months ended March 31, 2023. Equity-based compensation was recognized in all segments and Corporate for three months ended March 31, 2023 and 2022.

(2)

 

Includes (i) certain costs of professional advisors related to mergers, acquisitions, dispositions or joint ventures and (ii) fair value adjustments for contingent consideration liabilities related to acquired businesses and compensation expense for deferred consideration associated with selling shareholders that are required to retain our employees.

 

 

Such costs for the three months ended March 31, 2023 primarily related to professional advisor costs, which were approximately $8 million and related to our Events, Experiences & Rights and Representation segments and Corporate. Fair value adjustments for contingent consideration liabilities related to acquired businesses and acquisition earn-out adjustments of approximately $4 million, which primarily related to our Events, Experiences & Rights, Representation and Sport Data & Technology segments.

 

 

Such costs for the three months ended March 31, 2022 primarily related to fair value adjustments for contingent consideration liabilities related to acquired businesses and acquisition earn-out adjustments of approximately $8 million, which primarily related to our Events, Experiences & Rights and Representation segments. Professional advisor costs were approximately $5 million and related to all of our segments.

(3)

 

Includes costs related to certain litigation or regulatory matters in each of our segments and Corporate.

(4)

 

Includes certain costs related to our restructuring activities and non-cash impairment charges.

 

 

Such costs for the three months ended March 31, 2023 primarily relates to the restructuring expenses in our Events, Experiences & Rights and Representation segments and Corporate.

 

 

Such costs for the three months ended March 31, 2022 primarily relates to the restructuring expenses in our Events, Experiences & Rights and Representation segments.

(5)

 

Includes the net change in fair value for certain equity investments with and without readily determinable fair values, based on observable price changes.

(6)

 

Relates to losses from the 20% interest we retained in the restricted Endeavor Content business, which we sold in January 2022. For the three months ended March, 31, 2022, also relates to equity method losses from our investment in Learfield IMG College.

(7)

 

Relates to the gain recorded for the sale of the restricted Endeavor Content business, net of transactions costs of $15.0 million.

(8)

 

For the three months ended March 31, 2023, includes a $2.3 million benefit for the tax receivable agreement liability related to a change in estimates related to future TRA payments.

 

 

For the three months ended March, 31, 2022, includes a $53.5 million expense for the tax receivable agreement liability related to the expected realization of certain tax benefits after concluding that such TRA payments would be probable based on estimates of future taxable income over the terms of the TRA.

(9)

 

For the three months ended March 31, 2023, other was comprised primarily of gains of approximately $10 million on foreign currency exchange transactions, which related to all of our segments and Corporate; gains of approximately $6 million on the sales of certain businesses, which relates to our Events, Experiences & Rights segment; a gain of approximately $5 million from the resolution of a contingency; and a gain of approximately $3 million related to change in the fair value of forward foreign exchange contracts, which related to our Events, Experiences & Rights segment and Corporate.

 

 

For the three months ended March 31, 2022, other costs were comprised primarily of losses of approximately $5 million on foreign exchange transactions, which related to all of our segments and Corporate, an approximately $1 million loss related to change in the fair value of forward foreign exchange contracts, which related to Corporate and an approximately $1 million loss on disposal of an asset related to our Events, Experiences & Rights segment.

 

Investors: [email protected]

Press: [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Licensing (Sports) Sports Entertainment Marketing Communications Events/Concerts Other Entertainment Martial Arts Licensing (Entertainment)

MEDIA:

Logo
Logo

H&R Block Reports Fiscal 2023 Third Quarter Results; Provides Update on FY23

KANSAS CITY, Mo., May 09, 2023 (GLOBE NEWSWIRE) — H&R Block, Inc. (NYSE: HRB) (the “Company”) today released its financial results1 for the fiscal 2023 third quarter ended March 31, 2023.

  • For the third quarter, the Company delivered revenue of
    $2.1 billion
    , an increase of
    2%
    ;
    earnings per share from continuing operations
    2
    of $4.14, an increas
    e of 2%
    ; and adjusted earnings per share from continuing operations
    2
    of $4.20, an increase of 2%
  • Tax season ended with strong performance in DIY; Assisted realized 4% growth in net average charge alongside positive customer satisfaction metrics
  • The Company is updating its fiscal year 2023 outlook due to softer than expected industry volume, its own Assisted volume, and the expected impact of foreign exchange rates

“Tax season 2023 was not the return to normal as anticipated post-pandemic. Consumers adjusted to smaller refunds, and many shifted to balance due. The industry contracted as those not required to file didn’t, and there was an impact from the IRS’ extending the filing deadline in certain states,” said Jeff Jones, H&R Block’s president and chief executive officer. “Despite these unusual dynamics, we were pleased to see our strategy work in DIY, continued strong growth in our virtual Assisted offering, and the benefit from pricing power and positive customer sentiment in our Assisted business as we grew penetration with higher income filers.”

Fiscal 2023 Third Quarter Results and Key Financial Metrics

  • Total revenue of $2.1 billion, increased by $31.9 million, or 2%, to the prior year. The increase was primarily driven by a higher net average charge in the Assisted category, partially offset by lower software sales and a decline in online paid returns during the quarter compared to the prior year.
  • Total operating expenses of $1.2 billion increased by $52.8 million, primarily due to higher field wages and the timing of advertising, partially offset by lower bad debt, legal fees, and consulting and outsourced services.
  • Pretax income decreased by $6.4 million to $855.4 million.
  • Earnings per share from continuing operations2 increased from $4.06 to $4.14 and adjusted earnings per share from continuing operations2 increased from $4.11 to $4.20, due to fewer shares outstanding from share repurchases.

Capital Allocation

  • The Company has approximately $900.0 million remaining on its latest $1.25 billion share repurchase authorization available through fiscal year 2025.
  • As previously announced, a quarterly cash dividend of $0.29 per share will be paid on July 6, 2023 to shareholders of record as of June 7, 2023. H&R Block has paid quarterly dividends consecutively since the Company became public in 1962.

Since 2016, the Company has returned more than $3 billion to shareholders in the form of share repurchases and dividends, buying back over one third of its shares outstanding3.

Fiscal Year 2023 Outlook

“Due to lighter than expected Assisted client volumes this season, as well as an expected foreign exchange impact of about $20 million, we are updating our full year outlook. Despite this change, I’m pleased that we still expect EBITDA and EPS to grow,” said Tony Bowen, H&R Block’s chief financial officer. “As we have shared, regardless of nuances year to year, we produce significant cash flow, pay a growing dividend, and buy back a meaningful amount of shares. We are confident in our ability to drive ongoing value for shareholders with these practices.”

Due to softer industry volumes, the Company now expects:

  • Revenue to be in the range of $3.440 to $3.465 billion, from $3.535 to $3.585 billion
  • EBITDA4 to be in the range of $895 to $910 million, from $915 to $950 million
  • Adjusted diluted earnings per share4 to be in the range of $3.65 to $3.80, from $3.70 to $3.95

The Company continues to expect:

  • Effective tax rate to be approximately 22%
  • Double-digit adjusted earnings per share4 growth annually through 2025

Conference Call

A conference call for analysts, institutional investors, and shareholders will be held at 4:30 p.m. Eastern time on Tuesday, May 9, 2023. During the conference call the company will discuss fiscal 2023 third quarter results, tax season results, outlook, and give a general business update. To join live, participants must register at https://register.vevent.com/register/BI68ce638aa0fa4494a9cbc71e80cc3880. Once registered, the participant will receive a dial-in number and unique PIN to access the call. Please join approximately 5 minutes prior to the scheduled start time.

The call, along with a presentation for viewing, will also be webcast in a listen-only format for the media and public. The webcast can be accessed directly at https://edge.media-server.com/mmc/p/rmcscxmc and will be available for replay 2 hours after the call is concluded and continuing for 90 days.

About H&R Block

H&R Block, Inc. (NYSE: HRB) provides help and inspires confidence in its clients and communities everywhere through global tax preparation services, financial products, and small-business solutions. The company blends digital innovation with human expertise and care as it helps people get the best outcome at tax time and also be better with money using its mobile banking app, Spruce. Through Block Advisors and Wave, the company helps small-business owners thrive with year-round bookkeeping, payroll, advisory, and payment processing solutions. For more information, visit H&R Block News or follow @HRBlockNews on Twitter.

About Non-GAAP Financial Information

This press release and the accompanying tables include non-GAAP financial information. For a description of these non-GAAP financial measures, including the reasons management uses each measure, and reconciliations of these non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with generally accepted accounting principles, please see the section of the accompanying tables titled “Non-GAAP Financial Information.”

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the securities laws. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts. They often include words or variation of words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “commits,” “seeks,” “estimates,” “projects,” “forecasts,” “targets,” “calls for,” “would,” “will,” “should,” “goal,” “could” or “may” or other similar expressions. Forward-looking statements provide management’s current expectations or predictions of future conditions, events or results. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. They may include estimates of revenues, client trajectory, income, effective tax rate, earnings per share, cost savings, capital expenditures, dividends, share repurchases, liquidity, capital structure, market share, industry volumes or other financial items, descriptions of management’s plans or objectives for future operations, products or services, or descriptions of assumptions underlying any of the above. They also include the expected impact of the coronavirus (COVID-19) pandemic, including, without limitation, the impact on economic and financial markets, the Company’s capital resources and financial condition, the expected use of proceeds under the Company’s revolving credit facility, future expenditures, potential regulatory actions, such as extensions of tax filing deadlines or other related relief, changes in consumer behaviors and modifications to the Company’s operations related thereto. All forward-looking statements speak only as of the date they are made and reflect the Company’s good faith beliefs, assumptions and expectations, but they are not guarantees of future performance or events. Furthermore, the Company disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions, factors, or expectations, new information, data or methods, future events or other changes, except as required by law. By their nature, forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. Factors that might cause such differences include, but are not limited to a variety of economic, competitive and regulatory factors, many of which are beyond the Company’s control, that are described in our Annual Report on Form 10-K for the fiscal year ended June 30, 2022 in the section entitled “Risk Factors” and additional factors we may describe from time to time in other filings with the Securities and Exchange Commission. You may get such filings for free at our website at https://investors.hrblock.com. In addition, factors that may cause the Company’s actual estimated effective tax rate to differ from estimates include the Company’s actual results from operations compared to current estimates, future discrete items, changes in interpretations and assumptions the Company has made, future actions of the Company, or increases in applicable tax rates in jurisdictions where the Company operates. You should understand that it is not possible to predict or identify all such factors and, consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

1All amounts in this release are unaudited. Unless otherwise noted, all comparisons refer to the current period compared to the corresponding prior year period.

2All per share amounts are based on fully diluted shares at the end of the corresponding period. The company reports non-GAAP financial measures of performance, including adjusted earnings per share (EPS), earnings before interest, tax, depreciation, and amortization (EBITDA) from continuing operations, free cash flow, and free cash flow yield, which it considers to be useful metrics for management and investors to evaluate and compare the ongoing operating performance of the company. See “About Non-GAAP Financial Information” below for more information regarding financial measures not prepared in accordance with generally accepted accounting principles (GAAP).

3Shares outstanding calculated as of April 30, 2016.

4Adjusted Diluted Earnings Per Share (EPS) and earnings before interest, tax, depreciation, and amortization (EBITDA) from continuing operations are non-GAAP financial measures. Future period non-GAAP outlook includes adjustments for items not indicative of our core operations, which may include, without limitation, items described in the below section titled “Non-GAAP Financial Information” and in the accompanying tables. Such adjustments may be affected by changes in ongoing assumptions and judgments, as well as nonrecurring, unusual, or unanticipated charges, expenses or gains, or other items that may not directly correlate to the underlying performance of our business operations. The exact amounts of these adjustments are not currently determinable but may be significant. It is therefore not practicable to provide the comparable GAAP measures or reconcile this non-GAAP outlook to the most comparable GAAP measures.

For Further Information
     
Investor Relations:   Michaella Gallina, (816) 854-3022, [email protected]
    Jordyn Eskijian, (816) 854-5674, [email protected]
Media Relations:   Angela Davied, (816) 854-5798, [email protected]
    Heather Woodard, (660) 864-3836, [email protected]

FINANCIAL RESULTS (unaudited, in 000s – except per share amounts)
  Three months ended March 31,   Nine months ended March 31,
  2023   2022   2023   2022
REVENUES:              
U.S. tax preparation and related services:              
Assisted tax preparation $ 1,453,049     $ 1,392,142     $ 1,530,577     $ 1,456,594  
Royalties   150,163       158,786       161,337       169,548  
DIY tax preparation   167,022       175,184       182,330       188,455  
Refund Transfers   117,384       132,223       120,210       134,665  
Peace of Mind® Extended Service Plan   16,750       17,222       58,840       59,373  
Tax Identity Shield®   8,720       9,078       19,237       19,431  
Other   10,972       10,584       28,845       27,736  
Total U.S. tax preparation and related services   1,924,060       1,895,219       2,101,376       2,055,802  
Financial services:              
Emerald Card® and SpruceSM   44,358       50,660       68,448       103,748  
Interest and fee income on Emerald AdvanceSM   33,750       30,535       47,267       43,438  
Total financial services   78,108       81,195       115,715       147,186  
International   69,417       65,232       156,297       151,464  
Wave   22,064       20,111       66,651       58,745  
Total revenues $ 2,093,649     $ 2,061,757     $ 2,440,039     $ 2,413,197  
Compensation and benefits:              
Field wages   480,779       435,345       618,656       561,482  
Other wages   73,503       78,584       207,786       200,715  
Benefits and other compensation   100,368       91,051       169,477       146,708  
    654,650       604,980       995,919       908,905  
Occupancy   118,111       111,405       316,874       306,523  
Marketing and advertising   210,508       196,582       236,299       223,796  
Depreciation and amortization   32,313       36,116       98,660       107,462  
Bad debt   34,273       45,051       57,018       59,760  
Other   179,292       182,258       363,081       373,458  
Total operating expenses   1,229,147       1,176,392       2,067,851       1,979,904  
               
Other income (expense), net   13,224       238       21,020       1,989  
Interest expense on borrowings   (22,298 )     (23,746 )     (57,107 )     (69,661 )
Pretax income   855,428       861,857       336,101       365,621  
Income taxes   209,351       186,884       78,254       29,666  
Net income from continuing operations   646,077       674,973       257,847       335,955  
Net loss from discontinued operations   (2,648 )     (1,796 )     (6,418 )     (4,984 )
Net income $ 643,429     $ 673,177     $ 251,429     $ 330,971  
               
DILUTED EARNINGS PER SHARE              
Continuing operations $ 4.14     $ 4.06     $ 1.62     $ 1.92  
Discontinued operations   (0.02 )     (0.01 )     (0.04 )     (0.03 )
Consolidated $ 4.12     $ 4.05     $ 1.58     $ 1.89  
               
WEIGHTED AVERAGE DILUTED SHARES   155,561       165,612       158,488       174,142  
               
Adjusted diluted EPS(1) $ 4.20     $ 4.11     $ 1.80     $ 2.11  
EBITDA(1) $ 910,039     $ 921,719     $ 491,868     $ 542,744  
               

(1) All non-GAAP measures are results from continuing operations. See “Non-GAAP Financial Information” for a reconciliation of non-GAAP measures.

CONSOLIDATED BALANCE SHEETS   (unaudited, in 000s – except per share data)
As of   March 31, 2023   June 30, 2022
         
ASSETS        
Cash and cash equivalents   $ 909,075     $ 885,015  
Cash and cash equivalents – restricted     25,270       165,698  
Receivables, net     249,150       58,447  
Income taxes receivable     32,584       202,838  
Prepaid expenses and other current assets     86,736       72,460  
Total current assets     1,302,815       1,384,458  
Property and equipment, net     136,132       123,912  
Operating lease right of use assets     372,175       427,783  
Intangible assets, net     293,447       309,644  
Goodwill     769,557       760,401  
Deferred tax assets and income taxes receivable     226,527       208,948  
Other noncurrent assets     57,254       54,012  
Total assets   $ 3,157,907     $ 3,269,158  
LIABILITIES AND STOCKHOLDERS’ EQUITY        
LIABILITIES:        
Accounts payable and accrued expenses   $ 236,388     $ 160,929  
Accrued salaries, wages and payroll taxes     208,560       154,764  
Accrued income taxes and reserves for uncertain tax positions     284,124       280,115  
Operating lease liabilities     179,415       206,898  
Deferred revenue and other current liabilities     207,095       196,107  
Total current liabilities     1,115,582       998,813  
Long-term debt     1,488,457       1,486,876  
Deferred tax liabilities and reserves for uncertain tax positions     256,119       226,362  
Operating lease liabilities     199,086       228,820  
Deferred revenue and other noncurrent liabilities     135,055       116,656  
Total liabilities     3,194,299       3,057,527  
COMMITMENTS AND CONTINGENCIES        
STOCKHOLDERS’ EQUITY:        
Common stock, no par, stated value $.01 per share     1,854       1,936  
Additional paid-in capital     775,269       772,182  
Accumulated other comprehensive loss     (44,281 )     (21,645 )
Retained earnings (deficit)     (109,384 )     120,405  
Less treasury shares, at cost     (659,850 )     (661,247 )
Total stockholders’ equity (deficiency)     (36,392 )     211,631  
Total liabilities and stockholders’ equity   $ 3,157,907     $ 3,269,158  
         

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS   (unaudited, in 000s)
Nine months ended March 31,   2023   2022
         
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net income   $ 251,429     $ 330,971  
Adjustments to reconcile net income to net cash provided by operating activities:        
Depreciation and amortization     98,660       107,462  
Provision     49,174       59,778  
Deferred taxes     6,685       (85,122 )
Stock-based compensation     26,785       19,988  
Changes in assets and liabilities, net of acquisitions:        
Receivables     (237,395 )     (233,362 )
Prepaid expenses, other current and noncurrent assets     (17,438 )     (16,525 )
Accounts payable, accrued expenses, salaries, wages and payroll taxes     122,025       122,112  
Deferred revenue, other current and noncurrent liabilities     22,054       36,960  
Income tax receivables, accrued income taxes and income tax reserves     179,692       36,244  
Other, net     (3,285 )     (5,378 )
Net cash provided by operating activities     498,386       373,128  
         
CASH FLOWS FROM INVESTING ACTIVITIES:        
Capital expenditures     (56,661 )     (52,718 )
Payments made for business acquisitions, net of cash acquired     (47,740 )     (25,465 )
Franchise loans funded     (21,566 )     (18,468 )
Payments from franchisees     14,963       17,714  
Other, net     9,717       7,831  
Net cash used in investing activities     (101,287 )     (71,106 )
         
CASH FLOWS FROM FINANCING ACTIVITIES:        
Repayments of line of credit borrowings     (970,000 )     (705,000 )
Proceeds from line of credit borrowings     970,000       705,000  
Dividends paid     (133,762 )     (143,435 )
Repurchase of common stock, including shares surrendered     (365,852 )     (555,247 )
Proceeds from exercise of stock options     1,427       4,605  
Other, net     (7,400 )     (13,389 )
Net cash used in financing activities     (505,587 )     (707,466 )
         
Effects of exchange rate changes on cash     (7,880 )     (1,666 )
         
Net decrease in cash and cash equivalents, including restricted balances     (116,368 )     (407,110 )
Cash, cash equivalents and restricted cash, beginning of period     1,050,713       1,584,164  
Cash, cash equivalents and restricted cash, end of period   $ 934,345     $ 1,177,054  
         
SUPPLEMENTARY CASH FLOW DATA:        
Income taxes paid (received), net   $ (110,028 )   $ 76,894  
Interest paid on borrowings     59,429       58,009  
Accrued additions to property and equipment     4,378       1,336  
New operating right of use assets and related lease liabilities     131,949       126,726  
Accrued dividends payable to common shareholders     44,163       43,041  
         

(in 000s)
    Three months ended March 31,   Nine months ended March 31,
NON-GAAP FINANCIAL MEASURE – EBITDA   2023   2022   2023   2022
                 
Net income – as reported   $ 643,429   $ 673,177   $ 251,429   $ 330,971
Discontinued operations, net     2,648     1,796     6,418     4,984
Net income from continuing operations – as reported     646,077     674,973     257,847     335,955
Add back:                
Income taxes     209,351     186,884     78,254     29,666
Interest expense     22,298     23,746     57,107     69,661
Depreciation and amortization     32,313     36,116     98,660     107,462
      263,962     246,746     234,021     206,789
EBITDA from continuing operations   $ 910,039   $ 921,719   $ 491,868   $ 542,744
                 

(in 000s, except per share amounts)
    Three months ended March 31,   Nine months ended March 31,
NON-GAAP FINANCIAL MEASURE – ADJUSTED EPS   2023
  2022   2023
  2022
                 
Net income from continuing operations – as reported   $ 646,077     $ 674,973     $ 257,847     $ 335,955  
Adjustments:                
Amortization of intangibles related to acquisitions (pretax)     13,011       13,979       38,546       43,141  
Tax effect of adjustments(1)     (3,190 )     (4,545 )     (9,198 )     (10,102 )
Adjusted net income from continuing operations   $ 655,898     $ 684,407     $ 287,195     $ 368,994  
Diluted earnings per share from continuing operations – as reported   $ 4.14     $ 4.06     $ 1.62     $ 1.92  
Adjustments, net of tax     0.06       0.05       0.18       0.19  
Adjusted diluted earnings per share from continuing operations   $ 4.20     $ 4.11     $ 1.80     $ 2.11  
                 

(1)Tax effect of adjustments is the difference between the tax provision calculated on a GAAP basis and on an adjusted non-GAAP basis.

Non-GAAP Financial Information

Non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Because these measures are not measures of financial performance under GAAP and are susceptible to varying calculations, they may not be comparable to similarly titled measures for other companies.

We consider our non-GAAP financial measures to be performance measures and a useful metric for management and investors to evaluate and compare the ongoing operating performance of our business. We make adjustments for certain non-GAAP financial measures related to amortization of intangibles from acquisitions and goodwill impairments. We may consider whether other significant items that arise in the future should be excluded from our non-GAAP financial measures.

We measure the performance of our business using a variety of metrics, including earnings before interest, taxes, depreciation and amortization (EBITDA) from continuing operations, adjusted EBITDA from continuing operations, adjusted diluted earnings per share from continuing operations, free cash flow and free cash flow yield. We also use EBITDA from continuing operations and pretax income of continuing operations, each subject to permitted adjustments, as performance metrics in incentive compensation calculations for our employees.



RCM Technologies, Inc. Announces First-Quarter Results

PENNSAUKEN, N.J., May 09, 2023 (GLOBE NEWSWIRE) — RCM Technologies, Inc. (NasdaqGM: RCMT), a premier provider of business and technology solutions designed to enhance and maximize the operational performance of its customers through the adaptation and deployment of advanced engineering, specialty health care, and information technology services, today announced financial results for the thirteen weeks ended April 1, 2023.

RCM Technologies reported revenue of $67.1 million for the thirteen weeks ended April 1, 2023 (the current period), a decrease of 18.1% compared to $82.0 million for the thirteen weeks ended April 2, 2022 (the comparable prior-year period). Gross profit was $19.0 million for the current period, an 18.8% decrease compared to $23.4 million for the comparable prior-year period.  The Company experienced GAAP operating income of $5.7 million for the current period compared to $9.0 million for the comparable prior-year period.  The Company experienced GAAP net income of $3.8 million, or $0.41 per diluted share, for the current period compared to $6.5 million, or $0.62 per diluted share, for the comparable prior-year period. The Company experienced adjusted EBITDA (non-GAAP) of $5.6 million for the current period compared to $9.3 million for the comparable prior-year period.

Bradley Vizi, Executive Chairman of RCM Technologies, commented, “RCM started 2023 slower than we had expected, primarily due to project timing and program ramp-up in our Engineering segment. The cadence of activity has increased as we move through the first half of the year, allowing us to retain our offensive posture as we continue to build on the foundation carefully laid in each of our business units.”

Kevin Miller, Chief Financial Officer of RCM Technologies, commented, “As we expand our base, we believe that high return capital projects remain abundant both in the form of internal growth projects and bolt-on acquisitions that allow us to leverage the RCM platform.”



Conference Call



On Wednesday, May 10, 2023, RCM Technologies will host a conference call to discuss these results. The call will begin at 12:00 p.m. Eastern Time. The dial-in number is (800) 285-6670.



About RCM



RCM Technologies, Inc. is a premier provider of business and technology solutions designed to enhance and maximize the operational performance of its customers through the adaptation and deployment of advanced information technology and engineering services. RCM is an innovative leader in delivering these solutions to commercial and government sectors. RCM is also a provider of specialty healthcare services to major health care institutions and educational facilities. RCM’s offices are located in major metropolitan centers throughout North America and Serbia. Additional information can be found at www.rcmt.com.

The statements contained in this release that are not purely historical are forward-looking statements within the Private Securities Litigation Reform Act of 1995. They are subject to various risks, uncertainties, and other factors that could cause the Company’s actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as “may,” “will,” “expect,” “anticipate,” “continue,” “estimate,” “project,” “intend,” “believe,” “plan,” “seek,” “could,” “can,” “should,” “are confident” or similar expressions. In addition, statements that are not historical should also be considered forward-looking statements. These statements are based on assumptions that we have made in light of our experience in the industry, and our perceptions of historical trends, current conditions, expected future developments, and other factors we believe are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to demand for the Company’s services, expectations regarding our future revenues and other financial results, our pipeline, and potential project wins, and our expectations for investment and growth in our business. Such statements are based on current expectations that involve several known and unknown risks, uncertainties, and other factors, which may cause actual events to be materially different from those expressed or implied by such forward-looking statements. Risk, uncertainties, and other factors may emerge from time to time that could cause the Company’s actual results to differ from those indicated by the forward-looking statements. Investors are directed to consider such risks, uncertainties, and other factors described in documents filed by the Company with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company assumes no obligation (and expressly disclaims any such obligation) to update any forward-looking statements contained in this release as a result of new information or future events or developments, except as may be required by law.

Tables to Follow

RCM Technologies, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

(In Thousands, Except Per Share Amounts)

  Thirteen Weeks Ended
  April 1,

2023
  April 2,

2022
Revenue $67,124   $81,961
Cost of services 48,100   58,541
Gross profit 19,024   23,420
Selling, general and administrative 13,396   14,147
Depreciation and amortization of property and equipment 271   238
Amortization of acquired intangible assets 45  
Gain on sale of assets (395 )
Operating income 5,707   9,035
Other expense, net 407   52
Income before income taxes 5,300   8,983
Income tax expense 1,463   2,463
Net income $3,837   $6,520
       
Diluted net earnings per share data $0.41   $0.62
       

RCM Technologies, Inc.

Summary Consolidated Selected Balance Sheet Data

(In Thousands)

  April 1,

2023
  December 31,

2022
 
  (Unaudited)      
Cash and cash equivalents $1,825   $339  
Accounts receivable, net $58,809   $50,762  
Total current assets $68,806   $59,017  
Total assets $97,528   $87,964  
Total current liabilities $43,429   $40,424  
Borrowings under line of credit $19,151   $8,783  
Total liabilities $69,016   $56,002  
Treasury stock ($52,004 ) ($43,820 )
Stockholders’ equity $28,512   $31,962  

RCM Technologies, Inc.

Supplemental Operating Results on a Non-GAAP Basis

(Unaudited)

(In Thousands)

The following non-GAAP measures, which adjust for the categories of expenses described below, are non-GAAP financial measures.  Our management believes that these non-GAAP financial measures (“Adjusted operating income,” “EBITDA” and “Adjusted EBITDA”) are useful information for investors, shareholders, and other stakeholders of our Company in gauging our results of operations on an ongoing basis and to enhance investors’ overall understanding of our current financial performance and period-to-period comparisons.  Adjusted operating income, EBITDA and Adjusted EBITDA should not be considered alternatives to net income as an indicator of performance.  In addition, Adjusted operating income, EBITDA and Adjusted EBITDA do not take into account changes in certain assets and liabilities and interest and income taxes that can affect cash flows.  We do not intend the presentation of these non-GAAP measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP. These non-GAAP measures should be read-only in conjunction with our consolidated financial statements prepared in accordance with GAAP.

The following unaudited table presents the Company’s GAAP net income and the corresponding adjustments used to calculate Adjusted operating income, EBITDA and Adjusted EBITDA for the thirteen weeks ended April 1, 2023 and April 2, 2022. 

  Thirteen Weeks Ended  
  April 1,

2023
  April 2,
2022
 
GAAP net income $3,837   $6,520  
Income tax expense 1,463   2,463  
Interest expense, net 360   97  
Depreciation of property and equipment 271   238  
Amortization of acquired intangible assets 45    
EBITDA (non-GAAP) $5,976   $9,318  
         
Adjustments        
Gain on sale of assets (395 )  
Loss (gain) on foreign currency transactions 47   (45 )
Adjusted EBITDA (non-GAAP) $5,628   $9,273  



RCM Technologies, Inc.


Summary of Selected Income Statement Data

(Unaudited)

(In Thousands)

  Thirteen Weeks Ended April 1, 2023  
  Specialty
Health Care
  Engineering   Life Sciences
and IT
 
Consolidated
 
                 
Revenue $39,130   $18,490   $9,504   $67,124  
Cost of services 27,458   14,444   6,198   48,100  
Gross profit $11,672   $4,046   $3,306   $19,024  
Gross profit margin 29.8 % 21.9 % 34.8 % 28.3 %

  Thirteen Weeks Ended April 2, 2022  
  Specialty
Health Care
  Engineering   Life Sciences
and IT
 
Consolidated
 
                 
Revenue $52,184   $19,898   $9,879   $81,961  
Cost of services 37,183   14,664   6,694   58,541  
Gross profit $15,001   $5,234   $3,185   $23,420  
Gross profit margin 28.7 % 26.3 % 32.2 % 28.6 %
                 



RCM Technologies, Inc.


Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In Thousands)

  Thirteen Weeks Ended  
  April 1,

2023
  April 2,
2022
 
Net income $3,837   $6,520  
Adjustments to reconcile net income to cash used in operating activities 703   63  
Changes in operating assets and liabilities:        
Accounts receivable (8,035 ) (10,214 )
Prepaid expenses and other current assets 960   91  
Net of transit accounts receivable and payable 1,472   521  
Accounts payable and accrued expenses (2,196 ) (974 )
Accrued payroll and related costs 2,404   5,440  
Right of use liabilities (348 ) 117  
Income taxes payable 141   1,824  
Deferred revenue (310 ) (922 )
Deposits 11   2  
Total adjustments (5,198 ) (4,052 )
Net cash (used in) provided by operating activities (1,361 ) 2,468  
         
Net cash used in investing activities (332 ) (217 )
Net cash provided by (used in) financing activities 2,945   (1,612 )
Effect of exchange rate changes on cash and cash equivalents 234   (15 )
Increase in cash and cash equivalents $1,486   $624  

RCM Technologies, Inc. Tel: 856.356.4500
Corporate Contacts:
2500 McClellan Avenue Fax: 856.356.4600 Bradley S. Vizi
Pennsauken, NJ 08109 [email protected]
Executive Chairman
  www.rcmt.com Kevin D. Miller
   
Chief Financial Officer



Radius Global Infrastructure Reports First Quarter 2023 Results

Radius Global Infrastructure Reports First Quarter 2023 Results

Revenue Increased 35% YoY

NEW YORK–(BUSINESS WIRE)–
Radius Global Infrastructure, Inc. (Nasdaq: RADI) (“Radius” or the “Company”), one of the largest international owners and acquirors of real property interests and contractual rights underlying essential digital infrastructure assets, today reported financial results for the quarter ended March 31, 2023.

Bill Berkman, Co-Chairman and CEO of Radius Global Infrastructure, commented:

“We generated quarterly revenue of $41.2 million in the first quarter of 2023, up 35% from the first quarter of 2022, with gross profit increasing to $39.3 million, up 32% year-over-year. In the first quarter, our Annualized In-Place Rents increased by 32% to $165.8 million. Our revenues are primarily triple net, inflation-linked rents underlying mission-critical communications sites. In the first quarter of 2023, we acquired 186 communication sites through cash investments in real property interests and related intangible assets of $43.7 million, resulting in Acquisition Capex1 of $48.2 milion, which generated $3.7 million of annual rent. As of March 31, 2023, Radius has approximately $296.5 million of total cash and cash equivalents, restricted cash (including long-term restricted cash), and short-term investments.

RECENTLY ANNOUNCED TRANSACTION

As previously announced on March 1, 2023, Radius entered into a definitive agreement under which EQT Active Core Infrastructure (“EQT”) and the Public Sector Pension Investment Board (“PSP”), through certain of their controlled affiliates, will acquire the Company. This pending transaction is expected to close in the third quarter of 2023, subject to the satisfaction of certain closing conditions. For additional information relating to this pending transaction, please refer to the preliminary proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on April 7, 2023 and other relevant materials that the Company has filed and may file with the SEC in connection with this pending transaction.

QUARTERLY RESULTS

Revenue increased 35% to $41.2 million for the three months ended March 31, 2023, as compared to revenue of $30.6 million for the three months ended March 31, 2022. The increase was primarily attributable to the additional revenue streams acquired through investments in real property interests made during the past quarter, adjusted for foreign exchange rate effects.

Gross Profit rose 32% to $39.3 million during the three months ended March 31, 2023, as compared to gross profit of $29.8 million in the corresponding prior year period, reflecting a gross profit (which we also refer to as ground cash flow) margin of approximately 95% during the three months ending March 31, 2023. Ground cash flow margin was impacted by expenses associated with fee simple interests acquired, primarily for property taxes.

Annualized In-Place Rents (“AIPR”) increased to $165.8 million as of March 31, 2023, an increase of $40.4 million, or 32% over AIPR of $125.4 million as of March 31, 2022. On a constant currency basis, AIPR would have increased 35% year-over-year to $169.6 million as of March 31, 2023.

Investments in Real Property Interestsand Related Intangible Assets, as identified in the Company’s Consolidated Statements of Cash Flows, was $43.7 million and $73.1 million for the quarter ended March 31, 2023 and 2022, respectively, or a decrease of $29.4 million for the quarter ended March 31, 2023 over the prior period.

Acquisition Capex was $48.2 million and $74.6 million for the quarter ended March 31, 2023 and 2022, respectively, or a decrease of $26.4 million for the quarter ended March 31, 2023 over the prior period.

Please refer to the GAAP financial disclosures, reconciliations and comparisons to non-GAAP financial measurements set forth below and in the Company’s Form 10-Q for the quarter ended March 31, 2023.

LIQUIDITY

As of March 31, 2023, Radius had $296.5 million of total cash and cash equivalents, restricted cash (including long-term restricted cash), and short-term investments. Of this amount, approximately $273.4 million was available to deploy for asset acquisitions after excluding amounts that are required to be held in interest escrow accounts under certain long-term debt agreements.

OUTLOOK FOR 2023

As previously noted, the Company is not providing guidance with respect to the outlook for Acquisition Capex in 2023 in light of the pending transaction with EQT and PSP.

About the Company

Radius Global Infrastructure, Inc., through its various subsidiaries, is a multinational owner and acquiror of triple net rental streams and real properties leased to wireless operators, wired operators, wireless tower companies, and other digital infrastructure operators as part of their infrastructure required to deliver a wide range of services.

For further information see https://www.radiusglobal.com.

FORWARD-LOOKING STATEMENTS AND DISCLAIMERS

Certain matters discussed in this press release, including the attachments, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are subject to risks and uncertainties. For these statements, we claim the protections of the safe harbor for forward-looking statements contained in such Sections. These forward-looking statements include information about possible or assumed future results of our business, financial condition, liquidity, capital expenditures, plans and objectives, including with respect to capital allocation and organizational matters, and information about our proposed transaction with certain affiliates of EQT and PSP. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believe,” “expect,” “anticipate,” “estimate,” “outlook,” “plan,” “continue,” “intend,” “should,” “may,” “will,” or similar expressions, their negative or other variations or comparable terminology.

Forward-looking statements are subject to significant risks and uncertainties and are based on current beliefs, assumptions and expectations based upon our historical performance and on our current plans, estimates and expectations in light of information available to us. Any forward-looking statement speaks only as of the date on which it is made. Except as required by law, we are not obligated to, and do not intend to, publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are subject to various risks and uncertainties and assumptions relating to our operations, financial results, financial condition, business, prospects, growth strategy, liquidity and our proposed transaction with certain affiliates of EQT and PSP. Actual results may differ materially from those set forth in the forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Certain important factors that we think could cause our actual results to differ materially from expected results are summarized below. Other factors besides those summarized could also adversely affect us. We operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time and it is not possible for management to predict all such risks and uncertainties or how they may affect us. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Important other factors that could cause our actual results to differ materially from those expressed in or contemplated by the forward-looking statements include, but are not limited to: our proposed transaction with certain affiliates of EQT and PSP may not be completed in a timely manner or at all, including the risk that any required antitrust and foreign investment approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect us or the expected benefits of the proposed transaction or that the approval of our stockholders is not obtained; the possibility that any or all of the various conditions to the consummation of the proposed transaction may not be satisfied or waived, including the failure (a) to receive any required antitrust and foreign investment approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals) and (b) to satisfy conditions related to (i) there being no event of default under certain of the Company’s existing debt facilities, (ii) certain waivers of change of control provisions under certain of the debt agreements of the Company and its subsidiaries being in full force and effect at the closing, including the possibility that such waivers fail to be in full force and effect at the closing because any two of William H. Berkman, Scott G. Bruce and Richard I. Goldstein have ceased to continue in their current capacities as Chief Executive Officer, President and Chief Operating Officer of the Company, respectively, at the closing, and (iii) the Company having a specified minimum cash balance and the Company or any of its subsidiaries having an additional specified amount of additional cash, in each case at the closing; the possibility that compliance with the minimum cash condition to the consummation of the proposed transaction may limit the growth of the Company’s business, depending on the availability to the Company of other sources of capital that are permitted under the terms of the definitive agreement entered into in connection with the proposed transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the proposed transaction, including in circumstances that would require us to pay a termination fee or other expenses; the effect of the announcement or pendency of the proposed transaction on our ability to retain and hire key personnel, our ability to maintain the relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally; risks related to diverting management’s attention from our ongoing business operations; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; the extent that wireless carriers (mobile network operators, or “MNOs”) or tower companies consolidate their operations, exit the wireless communications business or share site infrastructure to a significant degree; the extent that new technologies reduce demand for wireless infrastructure; competition for assets; whether the tenant leases for the wireless communication tower, antennae or other digital communications infrastructure located on our real property interests are renewed with similar rates or at all; the extent of unexpected lease cancellations, given that most of the tenant leases associated with our assets may be terminated upon limited notice by the MNO or tower company and unexpected lease cancellations could materially impact cash flow from operations; economic, political, cultural, and regulatory risks and other risks to our operations, including risks associated with fluctuations in foreign currency exchange rates and local inflation rates; the effect of the Electronic Communications Code in the United Kingdom, which may limit the amount of lease income we generate in the United Kingdom; the extent that we continue to grow at an accelerated rate, which may prevent us from achieving profitability or positive cash flow at a company level (as determined in accordance with GAAP) for the foreseeable future, particularly given our history of net losses and negative net cash flow; the fact that we have incurred a significant amount of debt and may in the future incur additional indebtedness; the extent that the terms of our debt agreements limit our flexibility in operating our business; and the other factors, risks and uncertainties described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in our subsequent filings under the Exchange Act.

RADIUS GLOBAL INFRASTRUCTURE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

(in USD thousands, except share and per share amounts)

 

 

Three months

ended

March 31,

2023

 

 

Three months

ended

March 31,

2022

 

Revenue

 

$

41,214

 

 

$

30,599

 

Cost of service

 

 

1,892

 

 

 

841

 

Gross profit

 

 

39,322

 

 

 

29,758

 

Operating expenses:

 

 

 

 

 

 

Selling, general and administrative

 

 

29,464

 

 

 

22,687

 

Share-based compensation

 

 

5,184

 

 

 

4,592

 

Amortization and depreciation

 

 

23,085

 

 

 

18,751

 

Impairment – decommissions

 

 

1,050

 

 

 

765

 

Total operating expenses

 

 

58,783

 

 

 

46,795

 

Operating loss

 

 

(19,461

)

 

 

(17,037

)

Other income (expense):

 

 

 

 

 

 

Realized and unrealized gain (loss) on foreign currency debt

 

 

(15,479

)

 

 

24,232

 

Interest expense

 

 

(17,671

)

 

 

(16,098

)

Other income (expense), net

 

 

3,215

 

 

 

1,092

 

Total other income (expense), net

 

 

(29,935

)

 

 

9,226

 

Loss before income tax expense (benefit)

 

 

(49,396

)

 

 

(7,811

)

Income tax expense (benefit)

 

 

(1,584

)

 

 

(3,166

)

Net loss

 

 

(47,812

)

 

 

(4,645

)

Net loss attributable to noncontrolling interest

 

 

(2,227

)

 

 

(208

)

Net loss attributable to common stockholders

 

$

(45,585

)

 

$

(4,437

)

 

 

 

 

 

 

 

Loss per common share:

 

 

 

 

 

 

Basic and diluted

 

$

(0.48

)

 

$

(0.05

)

Weighted average common shares outstanding:

 

 

 

 

 

 

Basic and diluted

 

 

95,821,985

 

 

 

92,104,971

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

See accompanying notes to condensed consolidated financial statements.

RADIUS GLOBAL INFRASTRUCTURE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

(in USD thousands, except share and per share amounts)

 

 

March 31,

2023

 

 

December 31,

2022

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

197,879

 

 

$

224,258

 

Restricted cash

 

 

2,417

 

 

 

1,971

 

Short-term investments

 

 

34,612

 

 

 

39,205

 

Total cash, cash equivalents, restricted cash, and short-term investments

 

 

234,908

 

 

 

265,434

 

Trade receivables, net

 

 

11,317

 

 

 

8,200

 

Prepaid expenses and other current assets

 

 

29,747

 

 

 

28,773

 

Total current assets

 

 

275,972

 

 

 

302,407

 

Real property interests, net:

 

 

 

 

 

 

Right-of-use assets – finance leases, net

 

 

415,981

 

 

 

379,052

 

Telecom real property interests, net

 

 

1,582,164

 

 

 

1,569,676

 

Real property interests, net

 

 

1,998,145

 

 

 

1,948,728

 

Intangible assets, net

 

 

11,811

 

 

 

12,121

 

Property and equipment, net

 

 

1,291

 

 

 

1,241

 

Goodwill

 

 

80,509

 

 

 

80,509

 

Deferred tax asset

 

 

1,636

 

 

 

306

 

Restricted cash, long-term

 

 

61,595

 

 

 

88,054

 

Other long-term assets

 

 

21,209

 

 

 

20,124

 

Total assets

 

$

2,452,168

 

 

$

2,453,490

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

44,121

 

 

$

48,767

 

Rent received in advance

 

 

33,938

 

 

 

26,551

 

Finance lease liabilities, current

 

 

14,392

 

 

 

15,589

 

Telecom real property interest liabilities, current

 

 

4,564

 

 

 

7,975

 

Total current liabilities

 

 

97,015

 

 

 

98,882

 

Finance lease liabilities

 

 

21,768

 

 

 

22,277

 

Telecom real property interest liabilities

 

 

4,076

 

 

 

4,483

 

Long-term debt, net of debt discount and deferred financing costs

 

 

1,521,802

 

 

 

1,503,352

 

Deferred tax liability

 

 

134,238

 

 

 

131,229

 

Other long-term liabilities

 

 

11,585

 

 

 

10,473

 

Total liabilities

 

 

1,790,484

 

 

 

1,770,696

 

Commitments and contingencies

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Series A Founder Preferred Stock, $0.0001 par value; 1,600,000 shares authorized; 1,600,000

shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively

 

 

 

 

 

 

Series B Founder Preferred Stock, $0.0001 par value; 1,386,033 shares authorized; 1,386,033

shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively

 

 

 

 

 

 

Class A Common Stock, $0.0001 par value; 1,590,000,000 shares authorized; 99,541,524 and

95,283,563 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively

 

 

10

 

 

 

10

 

Class B Common Stock, $0.0001 par value; 200,000,000 shares authorized; 10,378,327 and

12,795,694 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively

 

 

 

 

 

 

Additional paid-in capital

 

 

1,082,943

 

 

 

1,060,055

 

Accumulated other comprehensive loss

 

 

(64,622

)

 

 

(85,936

)

Accumulated deficit

 

 

(384,404

)

 

 

(338,819

)

Total stockholders’ equity attributable to Radius Global Infrastructure, Inc.

 

 

633,927

 

 

 

635,310

 

Noncontrolling interest

 

 

27,757

 

 

 

47,484

 

Total liabilities and stockholders’ equity

 

$

2,452,168

 

 

$

2,453,490

 

See accompanying notes to condensed consolidated financial statements.

RADIUS GLOBAL INFRASTRUCTURE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

(in USD thousands)

 

 

Three months

ended

March 31,

2023

 

 

Three months

ended

March 31,

2022

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$

(47,812

)

 

$

(4,645

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Amortization and depreciation

 

 

23,085

 

 

 

18,751

 

Amortization of finance lease and telecom real property interest liabilities discount

 

 

460

 

 

 

367

 

Impairment – decommissions

 

 

1,050

 

 

 

765

 

Realized and unrealized gain on foreign currency debt

 

 

15,479

 

 

 

(24,232

)

Amortization of debt discount and deferred financing costs

 

 

1,715

 

 

 

1,106

 

Provision for bad debt expense

 

 

(64

)

 

 

98

 

Share-based compensation

 

 

5,184

 

 

 

4,592

 

Deferred income taxes

 

 

(3,446

)

 

 

(3,986

)

Change in assets and liabilities:

 

 

 

 

 

 

Trade receivables, net

 

 

(2,790

)

 

 

(1,707

)

Prepaid expenses and other assets

 

 

1,813

 

 

 

1,563

 

Accounts payable, accrued expenses and other long-term liabilities

 

 

(3,391

)

 

 

(1,309

)

Rent received in advance

 

 

6,700

 

 

 

3,978

 

Net cash used in operating activities

 

 

(2,017

)

 

 

(4,659

)

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

Investments in real property interests and related intangible assets

 

 

(43,688

)

 

 

(73,128

)

Advance deposits made for real property interest investments

 

 

(2,589

)

 

 

 

Proceeds from sales of real property interests

 

 

213

 

 

 

 

Proceeds from maturities of short-term investments

 

 

5,000

 

 

 

 

Purchases of property and equipment

 

 

(231

)

 

 

(195

)

Net cash used in investing activities

 

 

(41,295

)

 

 

(73,323

)

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

Borrowings under debt agreements

 

 

 

 

 

256,203

 

Repayments of term loans and other debt

 

 

 

 

 

(1,804

)

Debt issuance costs

 

 

 

 

 

(5,653

)

Proceeds from exercises of stock options

 

 

204

 

 

 

88

 

Repayments of finance lease and telecom real property interest liabilities

 

 

(11,075

)

 

 

(4,359

)

Net cash provided by (used in) financing activities

 

 

(10,871

)

 

 

244,475

 

 

 

 

 

 

 

 

Effect of change in foreign currency exchange rates on cash, cash equivalents

and restricted cash

 

 

1,791

 

 

 

(6,426

)

 

 

 

 

 

 

 

Net change in cash and cash equivalents and restricted cash

 

 

(52,392

)

 

 

160,067

 

 

 

 

 

 

 

 

Cash and cash equivalents and restricted cash at beginning of period

 

 

314,283

 

 

 

632,193

 

Cash and cash equivalents and restricted cash at end of period

 

$

261,891

 

 

$

792,260

 

 

 

 

 

 

 

 

Supplemental disclosure of cash and non-cash transactions:

 

 

 

 

 

 

Cash paid for interest

 

$

18,008

 

 

$

15,459

 

Cash paid for income taxes

 

$

373

 

 

$

150

 

See accompanying notes to condensed consolidated financial statements.

Non-GAAP Financial Measures

We use certain additional financial measures not defined by generally accepted accounting principles in the United States (“GAAP”) that provide supplemental information we believe is useful to analysts and investors to evaluate our financial performance and ongoing results of operations, when considered alongside other GAAP measures such as net income, operating income and gross profit. These non-GAAP measures exclude the financial impact of items management does not consider in assessing our ongoing operating performance, and thereby facilitate review of our operating performance on a period-to-period basis.

EBITDA and Adjusted EBITDA

EBITDA and Adjusted EBITDA are non-GAAP measures. EBITDA is defined as net income (loss) before interest expense, income tax expense (benefit), and depreciation and amortization. Adjusted EBITDA is calculated by taking EBITDA and further adjusting for non-cash impairment—decommissions expense, realized and unrealized gains and losses on foreign currency debt, realized and unrealized foreign exchange gains/losses associated with non-debt transactions and balances denominated in a currency other than the functional currency, share-based compensation expense and transaction-related costs recorded in selling, general and administrative expenses incurred for incremental business acquisition pursuits (successful and unsuccessful) and related financing and integration activities. Management believes the presentation of EBITDA and Adjusted EBITDA provides valuable additional information for users of the financial statements in assessing our financial condition and results of operations. Each of EBITDA and Adjusted EBITDA has important limitations as analytical tools because they exclude some, but not all, items that affect net income, therefore the calculation of these financial measures may be different from the calculations used by other companies and comparability may therefore be limited. You should not consider EBITDA, Adjusted EBITDA or any of our other non-GAAP financial measures as an alternative or substitute for our results.

The following are reconciliations of EBITDA and Adjusted EBITDA to net income (loss), the most comparable GAAP measure:

(in thousands)

 

Three months

ended

March 31,

2023

 

 

Three months

ended

March 31,

2022

 

(unaudited)

 

 

 

 

 

 

Net loss

 

$

(47,812

)

 

$

(4,645

)

Amortization and depreciation

 

 

23,085

 

 

 

18,751

 

Interest expense

 

 

17,671

 

 

 

16,098

 

Income tax expense (benefit)

 

 

(1,584

)

 

 

(3,166

)

EBITDA

 

 

(8,640

)

 

 

27,038

 

Impairment – decommissions

 

 

1,050

 

 

 

765

 

Realized and unrealized (gain) loss on foreign currency debt

 

 

15,479

 

 

 

(24,232

)

Share-based compensation expense

 

 

5,184

 

 

 

4,592

 

Non-cash foreign currency adjustments

 

 

(34

)

 

 

405

 

Transaction-related costs

 

 

7,195

 

 

 

140

 

Adjusted EBITDA

 

$

20,234

 

 

$

8,708

Acquisition Capex

Acquisition Capex is a non-GAAP financial measure. Our payments for acquisitions of real property interests consist of either a one-time payment upon the acquisition or up-front payments with contractually committed payments made over a period of time, pursuant to each real property interest agreement. In all cases, we contractually acquire all rights associated with the underlying revenue-producing assets upon entering into the agreement to purchase the real property interest and records the related assets in the period of acquisition. Acquisition Capex therefore represents the total cash spent and committed to be spent for the acquisitions of revenue-producing assets during the period measured. Management believes the presentation of Acquisition Capex provides valuable additional information for users of the financial statements in assessing our financial performance and growth, as it is a comprehensive measure of our investments in the revenue-producing assets that we acquire in a given period. Acquisition Capex has important limitations as an analytical tool, because it excludes certain fixed and variable costs related to our selling, marketing and underwriting activities included in selling, general and administrative expenses in the condensed consolidated statements of operations, including corporate overhead expenses. Further, this financial measure may be different from calculations used by other companies and comparability may therefore be limited. You should not consider Acquisition Capex or any of the other non-GAAP measures we utilize as an alternative or substitute for our results.

The following is a reconciliation of Acquisition Capex to the amounts included as an investing cash flow in the condensed consolidated statements of cash flows for investments in real property interests and related intangible assets, the most comparable GAAP measure, which generally represents up-front payments made in connection the acquisition of these assets during the period. The primary adjustment to the comparable GAAP measure is “committed contractual payments for investments in real property interests and intangible assets,” which represents the total amount of future payments that we were contractually committed to make in connection with our acquisitions of real property interests and intangible assets that occurred during the period. Additionally, foreign exchange translation adjustments impact the determination of Acquisition Capex.

(in thousands)

 

Three months

ended

March 31,

2023

 

 

Three months

ended

March 31,

2022

 

(unaudited)

 

 

 

 

 

 

Investments in real property interests and related

intangible assets

 

$

43,688

 

 

$

73,128

 

Committed contractual payments for investments

in real property interests and intangible assets

 

 

5,279

 

 

 

4,123

 

Foreign exchange translation impacts and other

 

 

(748

)

 

 

(2,614

)

Acquisition Capex

 

$

48,219

 

 

$

74,637

 

Annualized In-Place Rents

Annualized in-place rents is a non-GAAP measure that measures performance based on annualized contractual revenue from the rents expected to be collected on leases owned and acquired (“in place”) as of the measurement date. Annualized in-place rents is calculated using the implied monthly revenue from all revenue producing leases that are in place as of the measurement date multiplied by twelve. Implied monthly revenue for each lease is calculated based on the most recent rental payment under such lease. Management believes the presentation of annualized in-place rents provides valuable additional information for users of the financial statements in assessing our financial performance and growth. In particular, management believes the presentation of annualized in-place rents provides a measurement at the applicable point of time as opposed to revenue, which is recorded in the applicable period on revenue-producing assets in place as they are acquired. Annualized in-place rents has important limitations as an analytical tool because it is calculated at a particular moment in time, the measurement date, but implies an annualized amount of contractual revenue. As a result, following the measurement date, among other things, the underlying leases used in calculating the annualized in-place rents financial measure may be terminated, new leases may be acquired, or the contractual rents payable under such leases may not be collected. In these respects, among others, annualized in-place rents differs from “revenue,” which is the closest comparable GAAP measure and which represents all revenues (contractual or otherwise) earned over the applicable period. Revenue is recorded as earned over the period in which the lessee is given control over the use of the wireless communication sites and recorded over the term of the lease. You should not consider annualized in-place rents or any of the other non-GAAP measures we utilize as an alternative or substitute for our results. The following is a comparison of annualized in-place rents to revenue, the most comparable GAAP measure:

(in thousands)

 

Three months

ended

March 31,

2023

 

 

Year ended

December 31,

2022

 

(unaudited)

 

 

 

 

 

 

Revenue for year ended December 31

 

 

 

 

$

135,456

 

Annualized in-place rents as of December 31

 

 

 

 

$

157,553

 

Annualized in-place rents as of March 31

 

$

165,779

 

 

 

 

 

1 Please see page 9 for a definition of Acquisition Capex and reconciliation to Investments in Real Property Interests and Related Intangible Assets, the most comparable GAAP measure.

Investor Relations:

Jason Harbes, CFA

Email: [email protected]

Phone: 1-484-278-2667

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Technology Residential Building & Real Estate Telecommunications Commercial Building & Real Estate Construction & Property Urban Planning

MEDIA:

Logo
Logo

Energy Vault Reports First Quarter 2023 Earnings Results

Energy Vault Reports First Quarter 2023 Earnings Results

New project awards increased by ~$1 billion (2.8 GWh), of which ~$725 million (2 GWh) were gravity EVx systems

Recognized revenue of $11.4 million, in-line with expectations, and driven by construction progress of US-based BESS systems

GAAP gross margin of 21.2%, or $2.4 million, driven by the Company’s BESS project activity during the quarter

Reaffirm full-year 2023 financial guidance and project deliveries, including full-year revenue of $325 million to $425 million

On track for commissioning of first 100MWh commercial EVx, gravity-based energy storage system

First Quarter 2023 Financial Highlights

  • Revenue of $11.4 million, in-line with expectations, and driven by continued construction progress on BESS system projects in the US.

  • GAAP gross margin of 21.2%, or $2.4 million, driven by the Company’s BESS project activity during the quarter.

  • Net loss of $(31.2) million.

  • Adjusted EBITDA of $(19.0) million.

  • Total cash and cash equivalents on the balance sheet of $197.0 million and zero debt as of March 31, 2023.

  • Began execution on a new global relationship with Marsh, one of the world’s leading insurance brokers and risk advisors, to provide significant capital project surety and bonding capacity, inclusive Letters of Credit, on a fully non-collateralized cash basis allowing Energy Vault to convert remaining restricted cash balances from LOC’s to unrestricted cash.

  • The Company reiterates full year 2023 financial guidance and continues to expect total revenue of $325 million to $425 million, gross margin of 10% to 15%, adjusted EBITDA of $(50) million to $(70) million.

Operating and Other Highlights

  • Total near-term commercial funnel increased by over 40% or 11 GWh, quarter over quarter:

    • New project awards increased by 2.8 GWh or approximately $1 billion, a 78% increase from the prior quarter, of which, approximately $725 million relates to new gravity EVx systems

    • Submitted proposals and short-listed projects grew sequentially by 37% to approximately $12 billion and 35% to approximately $720 million, respectively

  • Construction of the first 100 MWh Energy Vault EVx gravity energy storage solution continues to advance rapidly in Rudong, China with expected mechanical completion and start of commissioning on track by the end of Q2 2023.

  • Construction progressed on the gravity EVx system in Snyder, Texas with our partner, Enel Green Power, with continued site equipment mobilization, piling activity and civil works for the foundation.

  • Announced the largest and “first of its kind” micro-grid hybrid storage solution with PG&E, California’s largest public utility, using green hydrogen and Energy Vault’s Energy Management System (EMS) to deliver multi-day energy storage to power the City of Calistoga. It is the largest green hydrogen system announced in the US for energy storage and aims to be one of the largest ultra-long duration energy storage (LDES) systems operating in the world when it comes online, targeted for mid-2024.

  • BESS projects of approximately 1 GWh announced in 2022 with Wellhead Electric, Jupiter Power and NV Energy continue to progress in line with customer commercial operation date (“COD”) expectations for turnover in the second half of 2023.

  • Cash usage during the quarter was driven primarily by planned project execution, including capex for previously announced owned projects with long term PPA or tolling agreements, working capital timing requirements for US battery projects under construction, and strategic investment capital.

    • Customer capex projects reflect the planned ongoing construction of the gravity EVx system in Snyder, Texas with our partner, Enel Green Power, and the Pacific Gas & Electric’s hybrid green hydrogen micro-grid for multi-day extended duration storage supporting the city of Calistoga, California, which recently received CPUC approval.

    • Project working capital reflects planned quarterly spending for the approximately 1 GWh of previously announced BESS projects booked in 2022 in Texas, California and Nevada for customers Jupiter Power, Wellhead, and Nevada Energy, all with planned COD in the second half of 2023.

    • Strategic investment in Q1 reflects an investment into a US provider of battery cells and modules, maximizing our local US supply chain flexibility and ensuring continuity of domestic US content supply for Energy Vault’s US customers at preferred economics, further amplified by the current IRA legislation.

LUGANO, Switzerland & WESTLAKE VILLAGE, Calif.–(BUSINESS WIRE)–
Energy Vault Holdings, Inc. (NYSE: NRGV) (“Energy Vault” or “the Company”), a leader in sustainable, grid-scale energy storage solutions, announced financial results for the first quarter ended March 31, 2023.

Robert Piconi, Chairman and CEO of Energy Vault, stated, “Following robust quarterly revenues of over $100 million in the fourth quarter of 2022, we had a strong commercial start to the year with impressive near term funnel growth dynamics and project awards of ~$1 billion while continuing our customer focus in executing on ~1 GWh of US battery projects on track for COD in the second half of 2023. We continue to make strong progress on our diverse range of projects, including the first deployment of the Company’s EVx gravity energy storage system (GESS) in China. During my recent trip to Rudong and Beijing in April, I had the opportunity to visit the site and witness the progress being made. We expect mechanical completion in Q2 2023 as previously anticipated and commencement of commissioning activities immediately afterwards.”

Mr. Piconi continued, “Looking ahead, we are laser focused on profitable and timely execution on our project portfolio to meet or exceed all customer requirements. I continue to be impressed with our team’s passion to serve our customers well. This is creating strong current customer references while also enabling additional project discussions to support our existing customer growth plans. This is underpinned by our technology-agnostic software platform and experienced team that can uniquely design solutions across short, long and ultra-long duration energy storage as the recent multi-day green hydrogen hybrid storage solution for PG&E demonstrates. Finally, we are optimistic about the magnitude of potential financial benefits from the Inflation Reduction Act (IRA) and the positive impact they can have to our existing forecast, in particular with our owned projects and what we have announced today with our investment into domestic US content battery supply chains. Overall, there are numerous tailwinds that reinforce my enthusiasm for our current position and our ability to drive long-term shareholder value.”

First Quarter 2023 and Recent Business Highlights:

  • Energy Vault and PG&E receive CPUC approval for Calistoga microgrid project: The California Public Utilities Commission (CPUC) has approved the request from Pacific Gas and Electric Company (PG&E), a subsidiary of PG&E Corporation (NYSE: PCG), for Energy Vault to deploy and operate a utility-scale battery plus green hydrogen long-duration energy storage system (BH-ESS). We expect the hybrid system to be capable of powering approximately 2,000 electricity customers within PG&E’s Calistoga microgrid for up to 96 hours (700 MWh of carbon-free energy) during a planned outage. This long-duration energy storage system is the “first-of-its-kind” and integrates a short duration battery system (for grid forming and black start capabilities) with a long duration liquid hydrogen-powered fuel cell system. The system is managed and dispatched by Energy Vault’s technology-agnostic Energy Management Software (EMS) to optimize performance and safety while minimizing operational cost. Further, the project is supported by a 10.5-year tolling agreement.
  • Executed a strategic investment in Kore Power, a US manufacturer of batteries cells and modules, to build supply continuity on a prioritized basis for domestic US content supply chains for Energy Vault’s US customers, supporting our short duration battery energy storage solutions on a preferred economic basis. In parallel with Energy Vault’s investment, we also executed a comprehensive battery supply agreement. This agreement will significantly benefit our domestic customers as envisioned with their IRA project eligibility. In Q4 2022, Energy Vault participated in the initial tranche as an undisclosed investor alongside Siemens Financial Services, Quanta Services, Honeywell Ventures and others. In Q1 2023 we made our second and final strategic investment.
  • Expanded previously announced Jupiter Power partnership to supply domestic US content of electrochemical battery modules from 2.4 GWh to 10 GWh, further strengthening the relationship with Jupiter to ensure supply chain priority on a 2-5 year planning horizon of project development while maximizing the financial benefits from the current IRA legislation.
  • On track for commercial deployment of all three of the battery energy storage systems (BESS) within customer stated COD dates: Our initial project with Wellhead Electric (275 MWh) is expected to be completed in Q3 2023. Subsequently, Jupiter Power (220 MWh) and NV Energy (440 MWh) projects are anticipated to be installed before the end of the year.

2023 Outlook:

Energy Vault is reiterating its previously announced 2023 financial outlook, including:

  • Energy Vault expects total revenue to be in the range of $325 million to $425 million, which reflects growth of approximately 2x to 3x over 2022.

  • Gross margin in the 10-15% range.

  • Adjusted EBITDA for the full-year 2023 is expected to be in the range of $(50) million to $(70) million.

Conference Call Information

Energy Vault will host a conference call today, May 9, 2023 at 4:30 PM ET to discuss the results, followed by a Q&A session. A live webcast of the call can be accessed at https://investors.energyvault.com/events-and-presentations/events. To access the call, participants may dial 1-877-704-4453, international callers may use 1-201-389-0920, and request to join the Energy Vault earnings call. A telephonic replay will be available shortly after the conclusion of the call and until, May 23, 2023. Participants may access the replay at 1-844-512-2921; international callers may use 1-412-317-6671, and enter access code 13737559. The call will also be available for replay via webcast link on the Investors portion of the Energy Vault website at https://www.energyvault.com/.

About Energy Vault

Energy Vault® develops and deploys utility-scale energy storage solutions designed to transform the world’s approach to sustainable energy storage. The Company’s comprehensive offerings include proprietary gravity-based storage, battery storage, and green hydrogen energy storage technologies. Each storage solution is supported by the Company’s hardware technology-agnostic energy management system software and integration platform. Unique to the industry, Energy Vault’s innovative technology portfolio delivers customized short-and-long-duration energy storage solutions to help utilities, independent power producers, and large industrial energy users significantly reduce levelized energy costs while maintaining power reliability. Utilizing eco-friendly materials with the ability to integrate waste materials for beneficial reuse, Energy Vault’s EVx™ gravity-based energy storage technology is facilitating the shift to a circular economy while accelerating the global clean energy transition for its customers. Please visit www.energyvault.com for more information.

Non-GAAP measures

Energy Vault has provided a reconciliation of net loss to adjusted EBITDA, with net loss being the most directly comparable GAAP measure, for the historical periods in this press release. A reconciliation of projected non-GAAP measures for the full-year 2023 has not been provided because certain information necessary to calculate such measures on a GAAP basis is unavailable or dependent on the timing of future events outside of our control. Therefore, because of the uncertainty and variability of the nature of the amount of future adjustments, which could be significant, the Company is unable to provide a reconciliation for these forward-looking non-GAAP measures without unreasonable effort.

Forward-Looking Statements

This press release includes forward-looking statements that reflect the Company’s current views with respect to, among other things, the Company’s operations and financial performance. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as “ anticipate,” “expect,” “suggest,” “plan,” “believe,” “intend,” “project,” “forecast,” “estimates,” “targets,” “projections,” “should,” “could,” “would,” “may,” “might,” “will” and other similar expressions. We base these forward-looking statements or projections on our current expectations, plans and assumptions, which we have made in light of our experience in our industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at the time. These forward-looking statements are based on our beliefs, assumptions and expectations of future performance, taking into account the information currently available to us. These forward-looking statements are only predictions based upon our current expectations and projections about future events. These forward-looking statements involve significant risks and uncertainties that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements, including changes in our strategy, expansion plans, customer opportunities, future operations, future financial position, estimated revenues and losses, projected costs, prospects and plans; the uncertainly of our bookings and backlogs equating to future revenue; the lack of assurance that non-binding letters of intent and other indication of interest can result in binding orders or sales; the possibility of our products to be or alleged to be defective or experience other failures; the implementation, market acceptance and success of our business model and growth strategy; our ability to develop and maintain our brand and reputation; developments and projections relating to our business, our competitors, and industry; the ability of our suppliers to deliver necessary components or raw materials for construction of our energy storage systems in a timely manner; the impact of health epidemics, on our business and the actions we may take in response thereto; our expectations regarding our ability to obtain and maintain intellectual property protection and not infringe on the rights of others; expectations regarding the time during which we will be an emerging growth company under the JOBS Act; our future capital requirements and sources and uses of cash; our ability to obtain funding for our operations and future growth; our business, expansion plans and opportunities and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on April 13, 2023, as such factors may be updated from time to time in its other filings with the SEC, accessible on the SEC’s website at www.sec.gov. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Any forward-looking statement made by us in this press release speaks only as of the date of this press release and is expressly qualified in its entirety by the cautionary statements included in this press release. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable laws. You should not place undue reliance on our forward-looking statements.

ENERGY VAULT HOLDINGS, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands except par value)

 

March 31,

2023

 

December 31,

2022

Assets

Current Assets

Cash and cash equivalents

$

114,556

 

 

$

203,037

 

Restricted cash

 

82,417

 

 

 

83,145

 

Accounts receivable, net

 

4,100

 

 

 

37,460

 

Contract assets, net

 

29,149

 

 

 

28,978

 

Inventory

 

4,899

 

 

 

4,378

 

Customer financing receivable, current portion, net

 

1,313

 

 

 

1,500

 

Advances to suppliers

 

95,341

 

 

 

24,327

 

Prepaid expenses and other current assets

 

6,779

 

 

 

7,242

 

Total current assets

 

338,554

 

 

 

390,067

 

Property and equipment, net

 

14,784

 

 

 

3,044

 

Operating lease right-of-use assets, net

 

1,266

 

 

 

1,442

 

Customer financing receivable, long-term portion, net

 

7,415

 

 

 

8,260

 

Other assets

 

20,442

 

 

 

13,900

 

Total Assets

$

382,461

 

 

$

416,713

 

Liabilities and Stockholders’ Equity

 

 

 

Current Liabilities

 

Accounts payable

$

8,427

 

 

$

60,315

 

Accrued expenses

 

19,490

 

 

 

14,749

 

Contract liabilities, current portion

 

86,027

 

 

 

49,434

 

Lease liabilities, current portion

 

825

 

 

 

825

 

Total current liabilities

 

114,769

 

 

 

125,323

 

Deferred pension obligation

 

734

 

 

 

890

 

Asset retirement obligation

 

444

 

 

 

560

 

Contract liabilities, long-term portion

 

1,500

 

 

 

1,500

 

Other long-term liabilities

 

529

 

 

 

727

 

Total liabilities

 

117,976

 

 

 

129,000

 

Stockholders’ Equity

 

 

 

Preferred stock, $0.0001 par value; 5,000 shares authorized, none issued

 

 

 

 

 

Common stock, $0.0001 par value; 500,000 shares authorized, 141,392 shares issued and outstanding at March 31, 2023; 138,530 shares issued and outstanding at December 31, 2022

 

14

 

 

 

14

 

Additional paid-in capital

 

445,870

 

 

 

435,852

 

Accumulated deficit

 

(180,796

)

 

 

(147,265

)

Accumulated other comprehensive loss

 

(603

)

 

 

(888

)

Total stockholders’ equity

 

264,485

 

 

 

287,713

 

Total Liabilities and Stockholders’ Equity

$

382,461

 

 

$

416,713

 

ENERGY VAULT HOLDINGS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands except per share data)

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

Revenue

$

11,422

 

 

$

42,884

 

Operating expenses:

 

 

 

Cost of revenue

 

9,003

 

 

 

 

Sales and marketing

 

4,574

 

 

 

2,580

 

Research and development

 

11,241

 

 

 

9,661

 

General and administrative

 

19,546

 

 

 

9,806

 

Loss from operations

 

(32,942

)

 

 

20,837

 

Other income (expense):

 

 

 

Interest expense

 

(1

)

 

 

(1

)

Change in fair value of warrant liability

 

 

 

 

(20,237

)

Transaction costs

 

 

 

 

(20,586

)

Other income, net

 

1,776

 

 

 

36

 

Loss before income taxes

 

(31,167

)

 

 

(19,951

)

Provision for income taxes

 

 

 

 

128

 

Net loss

$

(31,167

)

 

$

(20,079

)

 

 

 

 

Net loss per share — basic and diluted

$

(0.22

)

 

$

(0.25

)

Weighted average shares outstanding — basic and diluted

 

139,669

 

 

 

80,806

 

 

 

 

 

Other comprehensive income (loss) — net of tax

 

 

Actuarial gain on pension

$

164

 

 

$

278

 

Foreign currency translation gain (loss)

 

121

 

 

 

(94

)

Total other comprehensive income

 

285

 

 

 

184

 

Total comprehensive loss

$

(30,882

)

 

$

(19,895

)

ENERGY VAULT HOLDINGS, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

Cash Flows From Operating Activities

Net loss

$

(31,167

)

 

$

(20,079

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

Depreciation and amortization

 

209

 

 

 

1,218

 

Non-cash interest income

 

(334

)

 

 

(16

)

Stock based compensation

 

13,716

 

 

 

9,202

 

Change in fair value of warrant liability

 

 

 

 

20,237

 

Change in pension obligation

 

 

 

 

7

 

Change in asset retirement obligation

 

(119

)

 

 

19

 

Provision (benefit) for credit losses

 

(14

)

 

 

 

Foreign exchange gains and losses

 

170

 

 

 

19

 

Change in operating assets

 

(35,504

)

 

 

(32,550

)

Change in operating liabilities

 

(17,729

)

 

 

5,132

 

Net cash used in operating activities

 

(70,772

)

 

 

(16,811

)

Cash Flows From Investing Activities

 

Purchase of property and equipment

 

(11,635

)

 

 

(83

)

Purchase of equity securities

 

(6,000

)

 

 

 

Net cash used in investing activities

 

(17,635

)

 

 

(83

)

Cash Flows From Financing Activities

 

Proceeds from exercise of stock options

 

35

 

 

 

25

 

Proceeds from reverse recapitalization and PIPE financing, net

 

 

 

 

235,940

 

Payment of transaction costs related to reverse recapitalization

 

 

 

 

(20,651

)

Payment of taxes related to net settlement of equity awards

 

(800

)

 

 

 

Payment of finance lease obligations

 

(10

)

 

 

(10

)

Net cash provided by financing activities

 

(775

)

 

 

215,304

 

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

 

(27

)

 

 

(17

)

Net increase in cash, cash equivalents, and restricted cash

 

(89,209

)

 

 

198,393

 

Cash, cash equivalents, and restricted cash  –  beginning of the period

 

286,182

 

 

 

105,125

 

Cash, cash equivalents, and restricted cash –  end of the period

 

196,973

 

 

 

303,518

 

Less: Restricted cash at end of period

 

82,417

 

 

 

 

Cash and cash equivalents – end of period

$

114,556

 

 

$

303,518

 

 

 

 

 

Supplemental Disclosures of Cash Flow Information:

 

Income taxes paid

 

 

 

 

1

 

Cash paid for interest

 

1

 

 

 

23

 

Supplemental Disclosures of Non-Cash Investing and Financing Information:

 

 

 

Conversion of redeemable preferred stock into common stock in connection with the reverse recapitalization

 

 

 

 

182,034

 

Warrants assumed as part of reverse recapitalization

 

 

 

 

19,838

 

Actuarial gain on pension

 

164

 

 

 

278

 

Property, plant and equipment financed through accounts payable

 

4,021

 

 

 

137

 

Non-GAAP Financial Measure

We use adjusted EBITDA to complement our condensed consolidated statements of operations. Management believes that this non-GAAP financial measure complements our GAAP net loss and such measure is useful to investors. The presentation of this non-GAAP measure is not meant to be considered in isolation or as an alternative to net loss as an indicator of our performance.

The following table provides a reconciliation from net loss to non-GAAP adjusted EBITDA, with net loss being the most directly comparable GAAP measure (amounts in thousands):

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

Net loss (GAAP)

$

(31,167

)

 

$

(20,079

)

Non-GAAP Adjustments:

 

 

 

Interest income, net

 

(1,934

)

 

 

(47

)

Income tax expense

 

 

 

 

128

 

Depreciation and amortization

 

209

 

 

 

1,218

 

Stock-based compensation expense

 

13,716

 

 

 

9,202

 

Change in fair value of warrant liability

 

 

 

 

20,237

 

Transaction costs

 

 

 

 

20,586

 

Foreign exchange (gains) and losses

 

170

 

 

 

(11

)

Adjusted EBITDA (non-GAAP)

$

(19,006

)

 

$

31,234

 

We present adjusted EBITDA, which is net loss excluding adjustments that are outlined in the quantitative reconciliation provided above, as a supplemental measure of our performance and because we believe this measure is frequently used by securities analysts, investors, and other interested parties in the evaluation of companies in our industry. The items excluded from adjusted EBITDA are excluded in order to better reflect our continuing operations.

In evaluating adjusted EBITDA, one should be aware that in the future we may incur expenses similar to the adjustments noted above. Our presentation of adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these types of adjustments. Adjusted EBITDA is not a measurement of our financial performance under GAAP and should not be considered as an alternative to net loss, operating loss, or any other performance measures derived in accordance with GAAP or as an alternative to cash flow from operating activities as a measure of our liquidity.

Our adjusted EBITDA measure has limitations as an analytical tool, and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

  • it does not reflect our cash expenditures, future requirements for capital expenditures, or contractual commitments;

  • it does not reflect changes in, or cash requirements for, our working capital needs;

  • it does not reflect stock-based compensation, which is an ongoing expense;

  • although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and our adjusted EBITDA measure does not reflect any cash requirements for such replacements;

  • it is not adjusted for all non-cash income or expense items that are reflected in our condensed consolidated statements of cash flows;

  • it does not reflect the impact of earnings or charges resulting from matters we consider not to be indicative of our ongoing operations;

  • it does not reflect limitations on or costs related to transferring earnings from our subsidiaries to us; and

  • other companies in our industry may calculate this measure differently than we do, limiting its usefulness as a comparative measure.

Because of these limitations, adjusted EBITDA should not be considered as a measure of discretionary cash available to us to invest in the growth of our business or as a measure of cash that will be available to use to meet our obligations. You should compensate for these limitations by relying primarily on our GAAP results and using adjusted EBITDA only supplementally.

Investors:

[email protected]

Media:

[email protected]

KEYWORDS: California Europe Switzerland United States North America

INDUSTRY KEYWORDS: Other Energy Environment Utilities Sustainability Alternative Energy Energy

MEDIA:

American Vanguard Reports Q1 2023 Results

American Vanguard Reports Q1 2023 Results

Reaffirms Double-Digit Full-Year 2023 EBITDA Growth Despite Lower-Than-Expected Q1 Performance

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–
American Vanguard Corporation (NYSE: AVD) today announced financial results for the quarter ended March 31, 2023.

Q1 2023 Financial Performance – versus Q1 2022 (see table below):

Eric Wintemute, Chairman and CEO of American Vanguard, stated: “During 2023, we expect to achieve higher adjusted EBITDA (between $84MM – $86MM) than in 2022, despite a first quarter setback arising from delays in restarting our supply chain, which is now back at capacity. After experiencing multiple delays, our China-based supplier was unable to deliver intermediates in sufficient quantities for our leading corn soil insecticide, Aztec®, until early 2023. As a result, we were only able to produce and sell about one-third of seasonal demand for that product. This, coupled with a glut of generic herbicides (not sold by the Company) in the distribution channel, led to lower sales of domestic crop products during the quarter. While our domestic non-crop and international businesses recorded higher sales, the decrease in sales of higher-margin US crop products led to lower overall profitability.”

In thousands except for per share data

 

March 31, 2023

 

 

March 31, 2022

 

Change

 

Net sales

 

$

124,885

 

 

$

149,593

 

$

(24,708

)

Net income

 

$

1,918

 

 

$

9,935

 

$

(8,017

)

EPS

 

$

0.07

 

 

$

0.33

 

$

(0.26

)

Adjusted EBITDA1

 

$

11,511

 

 

$

22,867

 

$

(11,356

)

Mr. Wintemute continued, “Even after taking into account a lower-than-expected first quarter, we still expect full year 2023 will be stronger than 2022. With extremely low inventories of our domestic crop products in the distribution channel, we anticipate higher sales of US crop products in the second half of 2023. Further, we expect to continue the positive trajectories of our non-crop and international businesses. While below our original targets, our revised 2023 targets nevertheless show better year-over-year performance, as you can see from the table below.”

Mr. Wintemute continued, “For the sake of clarity, starting with this fiscal year, we have adopted an accounting change which is more prevalent among public companies in our sector under which outbound freight is classified as an element of cost of goods, as opposed to an operating expense. For us, these costs have typically been in the range of 7-8% of net sales. Thus, under this revised approach, our gross margin percent would decrease by that amount, and operating expenses as a percent of sales would decrease commensurately. This change has no effect upon operating income, adjusted EBITDA, net income or earnings per share.”

2023 Performance Targets

Metric

 

2023 Range

 

2022 Actual

 

% Change

Net sales

 

$640MM – $652MM

 

$610MM

 

5 to 7%

Gross margin %

 

33 to 35%

 

34%

 

Similar

Opex as % of sales

 

25 to 27%

 

25%

 

Similar

Adjusted EBITDA

 

$84MM – $86MM

 

$73MM

 

14 to 18%

Net income

 

$32MM – $34MM

 

$27.5MM

 

17 to 25%

Mr. Wintemute concluded: “We look forward to giving you a more detailed presentation during our upcoming earnings call, including with respect to our 2025 growth targets.”

Conference Call

Eric Wintemute, Chairman & CEO, Bob Trogele, COO, David T. Johnson, CFO, Scott Hendrix, U.S. Crop SVP and Jim Thompson, Leader of the Green Solutions Initiative, will conduct a conference call focusing on the financial results and strategic themes at 5:00 pm ET on May 9, 2023. Interested parties may participate in the call by dialing 713-481-1320. Please call in 10 minutes before the scheduled start time and ask for the American Vanguard call. The conference call will also be webcast live via the News and Media section of the Company’s web site at www.american-vanguard.com. To listen to the live webcast, go to the web site at least 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, the conference call will be archived on the Company’s web site.

About American Vanguard

American Vanguard Corporation is a diversified specialty and agricultural products company that develops, manufactures, and markets solutions for crop protection and nutrition, turf and ornamentals management, commercial and consumer pest control. American Vanguard is included on the Russell 2000® & Russell 3000® Indexes and the Standard & Poors Small Cap 600 Index. To learn more about American Vanguard, please reference the Company’s web site at www.american-vanguard.com.

The Company, from time to time, may discuss forward-looking information. Except for the historical information contained in this release, all forward-looking statements are estimates by the Company’s management and are subject to various risks and uncertainties that may cause results to differ from management’s current expectations. Such factors include weather conditions, changes in regulatory policy and other risks as detailed from time-to-time in the Company’s SEC reports and filings. All forward-looking statements, if any, in this release represent the Company’s judgment as of the date of this release.

 

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

 

 

 

March 31,

2023

 

 

December 31,

2022

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

19,568

 

 

$

20,328

 

Receivables:

 

 

 

 

 

 

Trade, net of allowance for doubtful accounts of $5,692 and $5,136, respectively

 

 

166,120

 

 

 

156,492

 

Other

 

 

9,999

 

 

 

9,816

 

Total receivables, net

 

 

176,119

 

 

 

166,308

 

Inventories

 

 

219,080

 

 

 

184,190

 

Prepaid expenses

 

 

15,324

 

 

 

15,850

 

Income taxes receivable

 

 

4,879

 

 

 

1,891

 

Total current assets

 

 

434,970

 

 

 

388,567

 

Property, plant and equipment, net

 

 

71,538

 

 

 

70,912

 

Operating lease right-of-use assets

 

 

24,460

 

 

 

24,250

 

Intangible assets, net

 

 

181,909

 

 

 

184,664

 

Goodwill

 

 

47,366

 

 

 

47,010

 

Other assets

 

 

10,610

 

 

 

10,769

 

Deferred income tax assets, net

 

 

220

 

 

 

141

 

Total assets

 

$

771,073

 

 

$

726,313

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

74,887

 

 

$

69,000

 

Customer prepayments

 

 

70,338

 

 

 

110,597

 

Accrued program costs

 

 

71,379

 

 

 

60,743

 

Accrued expenses and other payables

 

 

38,038

 

 

 

20,982

 

Operating lease liabilities, current

 

 

5,367

 

 

 

5,279

 

Total current liabilities

 

 

260,009

 

 

 

266,601

 

Long-term debt, net

 

 

97,000

 

 

 

51,477

 

Operating lease liabilities, long term

 

 

19,614

 

 

 

19,492

 

Other liabilities, net of current installments

 

 

4,648

 

 

 

4,167

 

Deferred income tax liabilities, net

 

 

14,808

 

 

 

14,597

 

Total liabilities

 

 

396,079

 

 

 

356,334

 

Commitments and contingent liabilities

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.10 par value per share; authorized 400,000 shares; none issued

 

 

 

 

 

 

Common stock, $0.10 par value per share; authorized 40,000,000 shares; issued 34,463,829 shares at March 31, 2023 and 34,446,194 shares at December 31, 2022

 

 

3,446

 

 

 

3,444

 

Additional paid-in capital

 

 

107,591

 

 

 

105,634

 

Accumulated other comprehensive loss

 

 

(9,636

)

 

 

(12,182

)

Retained earnings

 

 

329,812

 

 

 

328,745

 

Less treasury stock at cost, 5,057,727 shares at March 31, 2023 and 5,029,892 shares at December 31, 2022

 

 

(56,219

)

 

 

(55,662

)

Total stockholders’ equity

 

 

374,994

 

 

 

369,979

 

Total liabilities and stockholders’ equity

 

$

771,073

 

 

$

726,313

 

 

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

 
 

 

 

For the three months

ended March 31

 

 

 

2023

 

 

2022

 

Net sales

 

$

124,885

 

 

$

149,593

 

Cost of sales

 

 

(86,348

)

 

 

(98,198

)

Gross profit

 

 

38,537

 

 

 

51,395

 

Operating expenses

 

 

(35,272

)

 

 

(36,646

)

Operating income

 

 

3,265

 

 

 

14,749

 

Change in fair value of an equity investment

 

 

(22

)

 

 

83

 

Interest expense, net

 

 

(1,686

)

 

 

(398

)

Income before provision for income taxes

 

 

1,557

 

 

 

14,434

 

Income tax benefit (expense)

 

 

361

 

 

 

(4,499

)

Net income

 

$

1,918

 

 

$

9,935

 

Earnings per common share—basic

 

$

0.07

 

 

$

0.33

 

Earnings per common share—assuming dilution

 

$

0.07

 

 

$

0.33

 

Weighted average shares outstanding—basic

 

 

28,367

 

 

 

29,677

 

Weighted average shares outstanding—assuming dilution

 

 

29,073

 

 

 

30,349

 

 

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

ANALYSIS OF SALES

(Unaudited)

 

 

 

For the three Months Ended

March 31

 

 

 

2023

 

 

2022

 

 

Change

 

 

% Change

 

Net sales:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. crop

 

$

61,876

 

 

$

88,193

 

 

$

(26,317

)

 

 

-30

%

U.S. non-crop

 

 

13,899

 

 

 

13,396

 

 

 

503

 

 

 

4

%

Total U.S.

 

 

75,775

 

 

 

101,589

 

 

 

(25,814

)

 

 

-25

%

International

 

 

49,110

 

 

 

48,004

 

 

 

1,106

 

 

 

2

%

Total net sales:

 

$

124,885

 

 

$

149,593

 

 

$

(24,708

)

 

 

-17

%

Gross profit:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. crop

 

$

20,622

 

 

$

33,993

 

 

$

(13,371

)

 

 

-39

%

U.S. non-crop

 

 

5,446

 

 

 

5,767

 

 

 

(321

)

 

 

-6

%

Total U.S.

 

 

26,068

 

 

 

39,760

 

 

 

(13,692

)

 

 

-34

%

International

 

 

12,469

 

 

 

11,635

 

 

 

834

 

 

 

7

%

Total gross profit:

 

$

38,537

 

 

$

51,395

 

 

$

(12,858

)

 

 

-25

%

Gross margin:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

U.S. crop

 

 

33

%

 

 

39

%

 

 

 

 

 

 

 

 

U.S. non-crop

 

 

39

%

 

 

43

%

 

 

 

 

 

 

 

 

Total U.S.

 

 

34

%

 

 

39

%

 

 

 

 

 

 

 

 

International

 

 

25

%

 

 

24

%

 

 

 

 

 

 

 

 

Gross margin:

 

 

31

%

 

 

34

%

 

 

 

 

 

 

 

 

 

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

 

For the three months

ended March 31

 

 

 

2023

 

 

2022

 

Cash flows from operating activities:

 

 

 

 

 

 

Net income

 

$

1,918

 

 

$

9,935

 

Adjustments to reconcile net income to net cash used in operating

activities:

 

 

 

 

 

 

Depreciation and amortization of property, plant and equipment and intangible assets

 

 

5,539

 

 

 

5,230

 

Amortization of other long-term assets

 

 

714

 

 

 

1,173

 

Provision for bad debts

 

 

581

 

 

 

494

 

Fair value adjustment of contingent consideration

 

 

 

 

 

599

 

Stock-based compensation

 

 

1,474

 

 

 

1,563

 

Change in deferred income taxes

 

 

122

 

 

 

207

 

Change in liabilities for uncertain tax positions or unrecognized tax benefits

 

 

371

 

 

 

 

Other

 

 

94

 

 

 

2

 

Foreign currency transaction gains

 

 

(446

)

 

 

(261

)

Changes in assets and liabilities associated with operations:

 

 

 

 

 

 

Increase in net receivables

 

 

(8,779

)

 

 

(33,660

)

Increase in inventories

 

 

(33,731

)

 

 

(11,738

)

Decrease (increase) in prepaid expenses and other assets

 

 

600

 

 

 

(800

)

Change in income tax receivable/payable, net

 

 

(2,965

)

 

 

3,046

 

Increase in accounts payable

 

 

5,655

 

 

 

9,677

 

Decrease in customer prepayments

 

 

(22,759

)

 

 

(44,528

)

Increase in accrued program costs

 

 

10,660

 

 

 

24,601

 

(Decrease) increase in other payables and accrued expenses

 

 

(500

)

 

 

2,145

 

Net cash used in operating activities

 

 

(41,452

)

 

 

(32,315

)

Cash flows from investing activities:

 

 

 

 

 

 

Capital expenditures

 

 

(2,590

)

 

 

(3,294

)

Proceeds from disposal of property, plant and equipment

 

 

 

 

 

54

 

Acquisition of a product line

 

 

(703

)

 

 

 

Intangible assets

 

 

(15

)

 

 

(1,010

)

Net cash used in investing activities

 

 

(3,308

)

 

 

(4,250

)

Cash flows from financing activities:

 

 

 

 

 

 

Payments under line of credit agreement

 

 

(27,300

)

 

 

(12,000

)

Borrowings under line of credit agreement

 

 

72,000

 

 

 

58,000

 

Net receipt from the issuance of common stock under ESPP

 

 

480

 

 

 

436

 

Net receipt from the exercise of stock options

 

 

18

 

 

 

 

Receipt payment for tax withholding on stock-based compensation awards

 

 

(13

)

 

 

(2,174

)

Repurchase of common stock

 

 

(557

)

 

 

(6,219

)

Payment of cash dividends

 

 

(851

)

 

 

(594

)

Net cash provided by financing activities

 

 

43,777

 

 

 

37,449

 

Net (decrease) increase in cash and cash equivalents

 

 

(983

)

 

 

884

 

Effect of exchange rate changes on cash and cash equivalents

 

 

223

 

 

 

672

 

Cash and cash equivalents at beginning of period

 

 

20,328

 

 

 

16,285

 

Cash and cash equivalents at end of period

 

$

19,568

 

 

$

17,841

 

 

 

 

 

 

 

 

AMERICAN VANGUARD CORPORATION AND SUBSIDIARIES

RECONCILIATION OF NET INCOME TO EBITDA

(In thousands)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

Reconciliation of Net Income to EBITDA

 

2023

 

 

2022

 

Net income, as reported

 

$

1,918

 

 

$

9,935

 

Provision for income taxes

 

 

(361

)

 

 

4,499

 

Interest expense, net

 

 

1,686

 

 

 

398

 

Proxy costs

 

 

541

 

 

 

 

Depreciation and amortization

 

 

6,253

 

 

 

6,472

 

Stock compensation

 

 

1,474

 

 

 

1,563

 

Adjusted EBITDA2

 

$

11,511

 

 

$

22,867

 

1 Earnings before interest, taxes, depreciation, amortization and non-cash stock compensation. Adjusted EBITDA is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to net income (loss), operating income (loss) or any other financial measure so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. We provide these measures because we believe that they provide helpful comparisons to other companies in our industry and peer group. The items excluded from Adjusted EBITDA are detailed in the reconciliation attached to this news release, and reflect an elimination of taxes, interest, depreciation, amortization, the effects of equity compensation, and the proxy contest costs. Other companies (including the Company’s competitors) may define EBITDA differently.

2 Earnings before interest, taxes, depreciation, amortization and non-cash stock compensation. Adjusted EBITDA is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to net income (loss), operating income (loss) or any other financial measure so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. We provide these measures because we believe that they provide helpful comparisons to other companies in our industry and peer group. The items excluded from Adjusted EBITDA are detailed in the reconciliation attached to this news release, and reflect an elimination of taxes, interest, depreciation, amortization, the effects of equity compensation, and the proxy contest costs. Other companies (including the Company’s competitors) may define EBITDA differently.

Company Contact:

American Vanguard Corporation

William A. Kuser, Director of Investor Relations

(949) 260-1200

[email protected]

Investor Representative

the Equity Group Inc.

www.theequitygroup.com

Lena Cati / 212-836-9611

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Professional Services Insurance Finance

MEDIA:

Logo
Logo

Natera Reports First Quarter 2023 Financial Results

Natera Reports First Quarter 2023 Financial Results

AUSTIN, Texas–(BUSINESS WIRE)–
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the first quarter ended March 31, 2023.

Recent Strategic and Financial Highlights

  • Generated total revenues of $241.8 million in the first quarter of 2023, compared to $194.1 million in the first quarter of 2022, an increase of 24.5%. Product revenues grew 25.2% over the same period.

  • Processed approximately 626,200 tests in the first quarter of 2023, compared to approximately 489,300 tests in the first quarter of 2022, an increase of 28.0%.

  • Performed 71,000 oncology tests in the first quarter of 2023, compared to approximately 35,100 units in the first quarter of 2022, an increase of 102.2%.

  • Reinforced Panorama NIPT differentiation and data leadership with three papers (2 published, 1 accepted), including new evidence from the SMART study.

  • Received Medicare coverage for Prospera in heart transplantation.

  • Secured first commercial coverage decisions for Signatera, including pan-cancer coverage policy from Blue Shield of California.

  • New study published in Cancer highlights Signatera’s performance in stages III – IV melanoma.

  • Expanded I-SPY2study published in Cancer Cell demonstrates prognostic and predictive value of Signatera for breast cancer patients in the neoadjuvant setting.

  • Raising 2023 annual revenue guidance from $990 million to $1.0 billion to a new range of $995 million to $1.015 billion.

“We are off to an excellent start in 2023,” said Steve Chapman, Natera’s Chief Executive Officer. “We published important new data sets in the women’s health and oncology settings, received the first commercial coverage policies for Signatera, and secured Medicare reimbursement for Prospera in heart transplantation. Our performance demonstrates the strength of our technology, and we look forward to helping millions of additional patients and advancing our mission to transform the management of disease.”

First Quarter Ended March 31, 2023 Financial Results

Total revenues were $241.8 million in the first quarter of 2023, compared to $194.1 million for the first quarter of 2022, an increase of 24.5%. Product revenues were $237.8 million in the first quarter of 2023, compared to $190.0 million in the first quarter of 2022, an increase of 25.2%. The growth in product revenues was driven by an increase in test volumes compared to the first quarter of 2022.

Natera processed approximately 626,200 tests in the first quarter of 2023, including approximately 607,700 tests accessioned in its laboratory. This compares to approximately 489,300 tests processed in the first quarter of 2022, including approximately 473,200 tests accessioned in its laboratory, an increase of 28.0%.

In the three months ended March 31, 2023, Natera recognized revenue on approximately 583,400 tests for which results were reported to customers in the period (tests reported), including approximately 566,000 tests reported from its laboratory, compared to approximately 456,100 tests reported, including approximately 440,900 tests reported from its laboratory, in the first quarter of 2022, an increase of 27.9% for the quarter.

Gross profit* for the three months ended March 31, 2023 and 2022 was $93.6 million and $90.9 million, respectively, representing a gross margin of 38.7% and 46.8%. Natera had lower margins in the first quarter of 2023 compared to the first quarter of 2022 primarily due to increased labor, overhead costs, and third-party services driven by volume growth and product support.

Total operating expenses, representing research and development expenses and selling, general and administrative expenses, for the first quarter of 2023 were $231.9 million, compared to $228.0 million in the same period of the prior year, an increase of 1.7%. The increase was primarily driven by additional headcount to support the Company’s expansion, volume growth, and product development. Loss from operations for the first quarter of 2023 was $138.3 million, compared to $137.1 million for the same period of the prior year.

The Company reported a net loss for the first quarter of 2023 of $136.9 million, or ($1.23) per diluted share, compared to a net loss of $138.6 million, or ($1.45) per diluted share, for the same period in 2022. Weighted average shares outstanding were approximately 111.8 million in the first quarter of 2023, compared to 95.6 million in the first quarter of the prior year.

As of March 31, 2023, Natera held approximately $812.0 million in cash, cash equivalents, short-term investments and restricted cash, compared to $898.4 million as of December 31, 2022. As of March 31, 2023, Natera had a total outstanding debt balance of $362.4 million, comprised of $80.4 million including accrued interest under its line of credit with UBS at a variable interest rate of 30-day SOFR plus 121 basis points and a net carrying amount of $282.0 million under its seven-year convertible senior notes issued in April 2020. The gross principal balance outstanding for the convertible senior notes was $287.5 million as of March 31, 2023.

Financial Outlook

Natera is raising its expectations for 2023 total revenue from $980 million to $1.0 billion to a new range of $995 million to $1.015 billion, and continues to expect 2023 gross margin to be approximately 41% to 44% of revenues; selling, general and administrative costs to be approximately $510 million to $540 million; research and development costs to be $325 million to $345 million, and net cash consumption to be approximately $300 million to $325 million**.

* Gross profit is calculated as GAAP total revenues less GAAP cost of revenues. Gross margin is calculated as gross profit divided by GAAP total revenues.

** Cash consumption is calculated as the sum of GAAP net cash used by operating activities (estimated for 2023 to be approximately $250 million to $275 million) and GAAP net purchases of property and equipment (estimated for 2023 to be approximately $50 million).

Test Volume Summary

 

Unit

Q1 2023

Q1 2022

Definition

Tests processed

626,200

489,300

Tests accessioned in our laboratory plus units processed outside of our laboratory

Tests accessioned

607,700

473,200

Test accessioned in our laboratory

Tests reported in our laboratory

566,000

440,900

Total tests reported in our laboratory less units reported outside of our laboratory

Tests reported

583,400

456,100

Total tests reported

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Conference Call Information

Event:

Natera’s First Quarter 2023 Financial Results Conference Call

Date:

Tuesday, May 9, 2023

Time:

1:30 p.m. PT (4:30 p.m. ET)

Live Dial-In:

(888) 770-7321, Domestic

 

(929) 201-7107, International

Conference ID:

7684785

 

 

Webcast Link:

https://events.q4inc.com/attendee/726007467

Forward-Looking Statements

This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including the company’s financial guidance for fiscal 2022, its ability to continue to increase its revenues, its product development plans and its ability to maintain and grow its business operations in light of the COVID-19 pandemic, are forward-looking statements. Any forward-looking statements contained in this press release are based upon Natera’s current plans, estimates, and expectations, as of the date of this release, and are not a representation that such plans, estimates, or expectations will be achieved.

These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and challenges in achieving our financial projections and goals; we may be unable to further increase the use and adoption of our products through our direct sales efforts or through our laboratory partners; we have incurred losses since our inception and we anticipate that we will continue to incur losses for the foreseeable future; our quarterly results may fluctuate from period to period; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we may be unable to compete successfully with existing or future products or services offered by our competitors; we may engage in acquisitions, dispositions or other strategic transactions that may not achieve our anticipated benefits and could otherwise disrupt our business, cause dilution to our stockholders or reduce our financial resources; we may need to raise additional capital to support our business plans, which may not be available when necessary or on favorable terms; we may not be successful in commercializing our cloud-based distribution model; our products may not perform as expected; the results of our clinical studies, including our SNP-based Microdeletion and Aneuploidy RegisTry, or SMART, Study, may not be compelling to professional societies or payors as supporting the use of our tests, particularly for microdeletions screening, or may not be able to be replicated in later studies required for regulatory approvals or clearances; if either of our primary CLIA-certified laboratories becomes inoperable, we will be unable to perform our tests and our business will be harmed; we rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers; if we are unable to successfully scale our operations, our business could suffer; the marketing, sale, and use of Panorama and our other products could result in substantial damages arising from product liability or professional liability claims that exceed our resources; we may be unable to expand, obtain or maintain third-party payer coverage and reimbursement for Panorama, Horizon and our other tests, and we may be required to refund reimbursements already received; third-party payers may withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors; if the FDA were to begin actively regulating our tests, we could incur substantial costs and delays associated with trying to obtain premarket clearance or approval and incur costs associated with complying with post-market controls; litigation or other proceedings, including investigations, subpoenas, demands, disputes, litigation, requests for information and other regulatory or administrative actions or proceedings, or resulting from either third party claims of intellectual property infringement or asserting infringement by third parties of our technology, is costly, may result in substantial business and financial penalties, may be time-consuming and could limit our ability to commercialize our products or services; any inability to effectively protect our proprietary technology could harm our competitive position or our brand; and we cannot guarantee that we will be able to service and comply with our outstanding debt obligations or achieve our expectations regarding the conversion of our outstanding convertible notes.

Additional risks and uncertainties that could affect our financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our most recent filings on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time. These documents are available on our website at www.natera.com under the Investor Relations section and on the SEC’s website at www.sec.gov.

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Natera assumes no obligation to, and does not currently intend to, update any such forward-looking statements after the date of this release.

Natera, Inc.

Consolidated Balance Sheets

(Unaudited)

(in thousands, except par value per share amount)

 

 

 

March 31,

 

December 31,

 

 

2023

 

2022

 

 

 

(1)

Assets

 

 

 

 

Current assets:

 

 

 

 

Cash, cash equivalents and restricted cash

 

$

403,154

 

 

$

466,091

 

Short-term investments

 

 

408,858

 

 

 

432,301

 

Accounts receivable, net of allowance of $5,134 and $3,830 at March 31, 2023 and December 31, 2022, respectively

 

 

246,785

 

 

 

244,385

 

Inventory

 

 

40,683

 

 

 

35,406

 

Prepaid expenses and other current assets, net

 

 

29,988

 

 

 

33,634

 

Total current assets

 

 

1,129,468

 

 

 

1,211,817

 

Property and equipment, net

 

 

100,587

 

 

 

92,453

 

Operating lease right-of-use assets

 

 

69,537

 

 

 

71,874

 

Other assets

 

 

19,288

 

 

 

18,330

 

Total assets

 

$

1,318,880

 

 

$

1,394,474

 

Liabilities and Stockholders’ Equity

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable

 

$

36,123

 

 

$

31,148

 

Accrued compensation

 

 

39,231

 

 

 

44,010

 

Other accrued liabilities

 

 

118,638

 

 

 

144,214

 

Deferred revenue, current portion

 

 

16,579

 

 

 

10,777

 

Short-term debt financing

 

 

80,398

 

 

 

80,350

 

Total current liabilities

 

 

290,969

 

 

 

310,499

 

Long-term debt financing

 

 

281,973

 

 

 

281,653

 

Deferred revenue, long-term portion

 

 

21,511

 

 

 

20,001

 

Operating lease liabilities, long-term portion

 

 

73,854

 

 

 

76,577

 

Total liabilities

 

 

668,307

 

 

 

688,730

 

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

Common stock (2)

 

 

11

 

 

 

11

 

Additional paid-in capital

 

 

2,741,932

 

 

 

2,664,730

 

Accumulated deficit

 

 

(2,079,572

)

 

 

(1,942,635

)

Accumulated other comprehensive loss

 

 

(11,798

)

 

 

(16,362

)

Total stockholders’ equity

 

 

650,573

 

 

 

705,744

 

Total liabilities and stockholders’ equity

 

$

1,318,880

 

 

$

1,394,474

 

(1)

The consolidated balance sheet at December 31, 2022 has been derived from the audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

(2)

As of March 31, 2023 and December 31, 2022, there were approximately 113,359 and 111,255 shares of common stock issued and outstanding, respectively.

Natera, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(in thousands, except per share data)

 

 

 

Three months ended

 

 

March 31,

 

 

 

2023

 

 

 

2022

 

 

 

 

 

 

Revenues

 

 

 

 

Product revenues

 

$

237,797

 

 

$

190,002

 

Licensing and other revenues

 

 

3,959

 

 

 

4,131

 

Total revenues

 

 

241,756

 

 

 

194,133

 

Cost and expenses

 

 

 

 

Cost of product revenues

 

 

147,754

 

 

 

102,670

 

Cost of licensing and other revenues

 

 

370

 

 

 

545

 

Research and development

 

 

82,306

 

 

 

80,414

 

Selling, general and administrative

 

 

149,627

 

 

 

147,634

 

Total cost and expenses

 

 

380,057

 

 

 

331,263

 

Loss from operations

 

 

(138,301

)

 

 

(137,130

)

Interest expense

 

 

(3,061

)

 

 

(2,087

)

Interest and other income, net

 

 

4,585

 

 

 

801

 

Loss before income taxes

 

 

(136,777

)

 

 

(138,416

)

Income tax expense

 

 

(160

)

 

 

(179

)

Net loss

 

$

(136,937

)

 

$

(138,595

)

Unrealized gain (loss) on available-for-sale securities, net of tax

 

 

4,564

 

 

 

(11,617

)

Comprehensive loss

 

$

(132,373

)

 

$

(150,212

)

 

 

 

 

 

Net loss per share:

 

 

 

 

Basic and diluted

 

$

(1.23

)

 

$

(1.45

)

Weighted-average number of shares used in computing basic and diluted net loss per share:

 

 

 

 

Basic and diluted

 

 

111,767

 

 

 

95,578

 

 

Natera, Inc.

Investor Relations

Mike Brophy, CFO, Natera, Inc., 510-826-2350

Media

Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., [email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Oncology Medical Devices Health Consumer Women Genetics

MEDIA:

Logo
Logo

Electromed, Inc. Announces Fiscal 2023 Third Quarter Results

Electromed, Inc. Announces Fiscal 2023 Third Quarter Results

Quarterly Net Revenue Increase of 19% Year-over-Year

NEW PRAGUE, Minn.–(BUSINESS WIRE)–
Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ended March 31, 2023 (“Q3 FY 2023”).

Q3 FY 2023 Highlights

  • Record quarterly net revenues of $12.1 million, a 19% year-over-year increase

  • Homecare revenue of $11.0 million, an increase of 21% year-over-year

  • Generated operating income of $1.2 million, an increase of 39% year-over-year

  • Net income of $1.1 million, or $0.12 per fully diluted share, compared with net income of $645,000 in the same period a year ago

  • Cash as of March 31, 2023 was $6.8 million

“I’m very pleased to report 19% revenue growth in the third quarter of fiscal year 2023 coupled with net income growth that further demonstrates that our investments in growth are yielding strong results,” said Kathleen Skarvan, President and Chief Executive Officer. “Our revenue growth was driven by strong referral growth, improved productivity by our expanded sales team and the recent launch to the homecare market of our next generation SmartVest Clearway.”

Ms. Skarvan continued, “Our SmartVest Clearway has been received very positively by clinicians and patients due to its state-of-the-art patient experience with a simple touch screen user interface, remote monitoring of data, and is the lightest HFCWO generator on the market. We believe that Electromed is well-positioned for growth and profitability in calendar 2023.”

Fiscal Third Quarter Results

Net revenues for Q3 FY 2023 increased by 19% year-over-year to $12.1 million, compared with $10.1 million in the same period the prior year. The increase over the prior year was driven by an increase in referrals and approvals due to an expanded sales force and reimbursement team.

Home care revenue increased by $1,938,000, or 21.5%, for the three months ended March 31, 2023 compared to the same period in the prior year. The increase was primarily due to an increase in referrals and approvals. The increase in referrals was due to an increase in direct sales representatives as well as positive market momentum from the introduction of our newest generation SmartVest Clearway in the quarter and was partially offset by a temporary interruption in supply chain and associated operations in the quarter. Field sales force employees totaled 57 at quarter end, 48 of which were direct sales representatives. Sales productivity remained within our expected range during the quarter, with annualized home care revenues per direct sales representative at $908,000, within Electromed’s target range of $850,000 to $950,000.

Gross profit increased to $9,056,000, or 75.0% of net revenues, for the three months ended March 31, 2023, from $7,743,000, or 76.4% of net revenues, in the same period in the prior year. The decrease in gross profit as a percentage of net revenues compared to the same period in the prior year was primarily due to increased material costs and component broker fees incurred to ramp up supply for the Clearway product.

Selling, general and administrative (“SG&A”) expenses were $7,694,000 for the three months ended March 31, 2023, representing an increase of $1,150,000, or 17.6%, compared to the same period in the prior year. The increase in SG&A expense was primarily due to increased payroll and compensation expense related to the higher average number of sales, sales support, marketing, and reimbursement personnel to process higher patient referrals.

Operating income for the three months ended March 31, 2023 was $1,196,000, compared to $863,000 for the same period in the prior year. The increase in operating income was driven primarily by revenue growth and a decrease in Research & Development expenses but partially offset by increased SG&A expenses related to our sales and reimbursement investments, as well as increased material costs and broker fees incurred to accelerate the ramp up supply for the Clearway product.

Net income for the three months ended March 31, 2023 was $1,075,000, or $0.12 per diluted share, compared to $645,000, or $0.07 per diluted share, for the same period in the prior year.

As of March 31, 2023, Electromed had $6.8 million in cash, $22.3 million in accounts receivable, working capital of $28.8 million, and total shareholders’ equity of $36.4 million.

Conference Call and Webcast Information

The conference call will be held at 5:00 p.m. Eastern Time on Tuesday, May 9, 2023.

Interested parties may participate in the call by dialing (888) 999-5318 (Domestic) or (848) 280-6460 (International). The live conference call webcast will be accessible in the Investor Relations section of Electromed’s web site and directly via the following link: Fiscal Third Quarter Earnings Webcast.

For those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Domestic) or (412) 317-6671 (International) and referencing the replay pin number 0151926. Additionally, an online replay will be available in the Investor Relations section of Electromed’s web site at: http://investors.smartvest.com/.

About Electromed, Inc.

Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.

Cautionary Statements

Certain statements in this press release constitute forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “anticipate,” “assume,” “believe,” “continue,” “expect,” “may,” “potential,” “should,” “will,” and similar expressions, including the negative of these terms, but they are not the exclusive means of identifying such statements. Forward-looking statements cannot be guaranteed, and actual results may vary materially due to the uncertainties and risks, known or unknown associated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, component or raw material shortages, changes to lead times or significant price increases, changes to Medicare, Medicaid, or private insurance reimbursement policies; the duration, extent and severity of the COVID-19 pandemic, including its effects on our business, supply chain, operations and employees as well as its impact on our customers and distribution channels and on economies and markets more generally; the competitive nature of our market; changes to state and federal health care laws; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the homecare distributor channel; our need to maintain regulatory compliance and to gain future regulatory approvals and clearances; new drug or pharmaceutical discoveries; general economic and business conditions; our ability to renew our line of credit or obtain additional credit as necessary; our ability to protect and expand our intellectual property portfolio; the risks associated with expansion into international markets, as well as other factors we may describe from time to time in Electromed’s reports filed with the Securities and Exchange Commission (including Electromed’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all of the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.

Source: Electromed, Inc.

Financial Tables Follow:

Electromed, Inc.

 

Condensed Balance Sheets

March 31, 2023

June 30,

2022

(Unaudited)

Assets

Current Assets

Cash and cash equivalents

$

6,776,000

$

8,153,000

Accounts receivable (net of allowances for doubtful accounts of $45,000)

 

22,345,000

 

21,052,000

Contract assets

 

570,000

 

286,000

Inventories

 

3,451,000

 

3,178,000

 

 

Prepaid expenses and other current assets

 

1,808,000

 

 

1,870,000

Income tax receivable

 

219,000

 

Total current assets

 

35,169,000

 

34,539,000

Property and equipment, net

 

5,502,000

 

4,568,000

Finite-life intangible assets, net

 

604,000

 

599,000

Other assets

 

60,000

 

120,000

Deferred income taxes

 

1,506,000

 

1,538,000

Total assets

$

42,841,000

$

41,364,000

 

Liabilities and Shareholders’ Equity

Current Liabilities

Accounts payable

 

1,289,000

 

1,261,000

Accrued compensation

 

2,082,000

 

2,742,000

Income tax payable

 

 

51,000

Warranty reserve

 

1,333,000

 

1,256,000

Other accrued liabilities

 

1,713,000

 

1,840,000

Total current liabilities

 

6,417,000

 

7,150,000

Other long-term liabilities

 

30,000

 

41,000

Total liabilities

 

6,447,000

 

7,191,000

 

Commitments and Contingencies

 

Shareholders’ Equity

Common stock, $0.01 par value per share, 13,000,000 shares authorized;

8,556,600 and 8,475,438 shares issued and outstanding, as of March 31, 2023 and June 30, 2022, respectively

 

86,000

 

85,000

Additional paid-in capital

 

18,548,000

 

18,308,000

Retained earnings

 

17,760,000

 

15,780,000

Total shareholders’ equity

 

36,394,000

 

34,173,000

Total liabilities and shareholders’ equity

$

42,841,000

$

41,364,000

Electromed, Inc.

 

Condensed Statements of Operations (Unaudited)

Three Months Ended

Nine Months Ended

March 31,

March 31,

2023

2022

2023

2022

Net revenues

$

12,068,000

$

10,141,000

$

34,455,000

$

30,390,000

Cost of revenues

 

3,012,000

 

2,398,000

 

8,386,000

 

7,066,000

Gross profit

 

9,056,000

 

7,743,000

 

26,069,000

 

23,324,000

 

Operating expenses

Selling, general and administrative

 

7,694,000

 

6,544,000

 

22,937,000

 

19,806,000

Research and development

 

166,000

 

336,000

 

618,000

 

1,041,000

Total operating expenses

 

7,860,000

 

6,880,000

 

23,555,000

 

20,847,000

Operating income

 

1,196,000

 

863,000

 

2,514,000

 

2,477,000

Interest income, net

 

26,000

 

6,000

 

37,000

 

21,000

Net income before income taxes

 

1,222,000

 

869,000

 

2,551,000

 

2,498,000

 

Income tax expense

 

147,000

 

224,000

 

418,000

 

576,000

 

Net income

$

1,075,000

$

645,000

$

2,133,000

$

1,922,000

 

 

 

 

Income per share:

Basic

$

0.13

$

0.08

$

0.25

$

0.23

 

Diluted

$

0.12

$

0.07

$

0.25

$

0.22

 

Weighted-average common shares outstanding:

Basic

 

8,461,531

 

8,454,504

 

8,449,623

 

8,485,856

Diluted

 

8,710,106

 

8,744,535

 

8,694,407

 

8,762,963

Electromed, Inc.

 

Condensed Statements of Cash Flows (Unaudited)

 

Nine Months Ended March 31,

2023

2022

Cash Flows From Operating Activities

Net income

$

2,133,000

 

$

1,922,000

 

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation

 

370,000

 

 

368,000

 

Amortization of finite-life intangible assets

 

52,000

 

 

105,000

 

Share-based compensation expense

 

506,000

 

 

703,000

 

Deferred income taxes

 

32,000

 

 

15,000

 

Changes in operating assets and liabilities:

Accounts receivable

 

(1,293,000

)

 

(2,582,000

)

Contract assets

 

(284,000

)

 

98,000

 

Inventories

 

(264,000

)

 

9,000

 

Prepaid expenses and other assets

 

105,000

 

 

(519,000

)

Income tax receivable, net

 

(270,000

)

 

(443,000

)

Accounts payable and accrued liabilities

 

(111,000

)

 

550,000

 

Accrued compensation

 

(660,000

)

 

(173,000

)

Net cash provided by operating activities

 

316,000

 

 

53,000

 

 

Cash Flows From Investing Activities

Investment in property and equipment

 

(1,221,000

)

 

(980,000

)

Investment in finite-life intangible assets

 

(54,000

)

 

(86,000

)

Net cash used in investing activities

 

(1,275,000

)

 

(1,066,000

)

 

Cash Flows From Financing Activities

Issuance of common stock upon exercise of options

 

40,000

 

 

 

Taxes paid on stock options exercised on a net basis

 

(305,000

)

 

(70,000

)

Repurchase of common stock

 

(153,000

)

 

(962,000

)

Net cash used in financing activities

 

(418,000

)

 

(1,032,000

)

Net (decrease) increase in cash

 

(1,377,000

)

 

(2,045,000

)

 

Cash And Cash Equivalents

Beginning of period

 

8,153,000

 

 

11,889,000

 

End of period

$

6,776,000

 

$

9,844,000

 

 

Brad Nagel, Chief Financial Officer

(952) 758-9299

[email protected]

Mike Cavanaugh, Investor Relations

ICR Westwicke

(617) 877-9641

[email protected]

KEYWORDS: Minnesota United States North America

INDUSTRY KEYWORDS: General Health Health Medical Devices

MEDIA:

Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update

Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update

– Total Revenues of $408.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $363.4 million –

– GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.16 –

– Conference Call and Webcast Today at 5:00 PM Eastern Time –

ALAMEDA, Calif.–(BUSINESS WIRE)–
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.

“The Exelixis team continued to execute on our key priorities and made significant progress in advancing our commercial business and our growing pipeline,” said Michael M. Morrissey, Ph.D., President and Chief Executive Officer, Exelixis. “CABOMETYX® maintained its status as the leading tyrosine kinase inhibitor in renal cell carcinoma in the first quarter, driven by its use in combination with nivolumab in the first-line setting. We’ve made important progress across our pipeline programs, including advancing the STELLAR-303 and STELLAR-304 phase 3 trials for zanzalintinib, as well as single-agent and combination dose-escalation cohorts of the phase 1 trial of XB002. We are on track to initiate additional pivotal studies for zanzalintinib in 2023 and are focused on accelerating XB002 into full development by year-end.”

Dr. Morrissey continued: “Our collaborations with Cybrexa and Sairopa also made steady progress. Sairopa received clearance of its Investigational New Drug application for ADU-1805 from the U.S. Food and Drug Administration in February and subsequently initiated the phase 1 study in March. Cybrexa is planning to present updated phase 1 data for CBX-12 at the ASCO Annual Meeting in June. In March, we announced a share repurchase program for up to $550 million of our common stock before the end of 2023, which reflects continued confidence in our long-term prospects and the strength of our balance sheet and reinforces our commitment to deliver value to shareholders. I’d like to thank the entire Exelixis team for their collective hard work and dedication to improving the standard-of-care for patients while driving sustainable, long-term value for shareholders as we advance our mission to help cancer patients recover stronger and live longer.”

First Quarter 2023 Financial Results

Total revenues for the quarter ended March 31, 2023 were $408.8 million, as compared to $356.0 million for the comparable period in 2022.

Total revenues for the quarter ended March 31, 2023 included net product revenues of $363.4 million, as compared to $310.3 million for the comparable period in 2022. The increase in net product revenues was primarily due to an increase in sales volume and an increase in average net selling price.

Collaboration revenues, composed of license revenues and collaboration services revenues, were $45.4 million for the quarter ended March 31, 2023, as compared to $45.7 million for the comparable period in 2022. The decrease in collaboration revenues was primarily related to a decrease in development cost reimbursements earned, which was offset by higher royalty revenues for the sales of cabozantinib outside of the U.S. generated by Exelixis’ collaboration partners, Ipsen Pharma SAS and Takeda Pharmaceutical Company Limited.

Research and development expenses for the quarter ended March 31, 2023 were $234.2 million, as compared to $156.7 million for the comparable period in 2022. The increase in research and development expenses was primarily related to increases in license and other collaboration costs, personnel expenses and manufacturing costs to support our development candidates, which were partially offset by lower stock-based compensation expense.

Selling, general and administrative expenses for the quarter ended March 31, 2023 were $131.4 million, as compared to $102.9 million for the comparable period in 2022. The increase in selling, general and administrative expenses was primarily related to an increase in personnel expenses.

Provision for income taxes for the quarter ended March 31, 2023 was $8.3 million, as compared to $16.7 million for the comparable period in 2022, primarily due to a decrease in pre-tax income.

GAAP net income for the quarter ended March 31, 2023 was $40.0 million, or $0.12 per share, basic and diluted, as compared to GAAP net income of $68.6 million, or $0.21 per share, basic and diluted, for the comparable period in 2022.

Non-GAAP net income for the quarter ended March 31, 2023 was $52.8 million, or $0.16 per share, basic and diluted, as compared to non-GAAP net income of $83.9 million, or $0.26 per share, basic and diluted, for the comparable period in 2022.

Non-GAAP Financial Measures

To supplement Exelixis’ financial results presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Exelixis presents non-GAAP net income (and the related per share measures), which excludes from GAAP net income (and the related per share measures) stock-based compensation expense, adjusted for the related income tax effect for all periods presented.

Exelixis believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. In particular, Exelixis believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare Exelixis’ results from period to period, and to identify operating trends in Exelixis’ business. Exelixis has excluded stock-based compensation expense, adjusted for the related income tax effect, because it is a non-cash item that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Exelixis also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions.

These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Exelixis encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations, to more fully understand Exelixis’ business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.

2023 Financial Guidance

Exelixis is maintaining the previously provided financial guidance for fiscal year 2023:

Total revenues

 

$1.775 billion – $1.875 billion

Net product revenues

 

$1.575 billion – $1.675 billion

Cost of goods sold

 

4.0% – 5.0% of net product revenues

Research and development expenses (1)

 

$1,000 million – $1,050 million

Selling, general and administrative expenses (2)

 

$475 million – $525 million

Effective tax rate

 

20% – 22%

____________________

(1)

Includes $45 million of non-cash stock-based compensation expense.

(2)

Includes $55 million of non-cash stock-based compensation expense.

Cabozantinib Highlights

Cabozantinib Franchise Net Product Revenues and Royalties. Net product revenues generated by the cabozantinib franchise in the U.S. were $363.4 million during the first quarter of 2023, with net product revenues of $361.8 million from CABOMETYX® (cabozantinib) and $1.6 million from COMETRIQ® (cabozantinib). Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter ended March 31, 2023, Exelixis earned $32.7 million in royalty revenues.

Cabozantinib Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (ASCO GU 2023). In February, cabozantinib was the subject of multiple data presentations at ASCO GU 2023, held from February 16-18, 2023. Notable presentations included: 44-month median follow-up data and biomarker analyses from CheckMate -9ER, the phase 3 pivotal trial of cabozantinib in combination with nivolumab; outcomes by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score in COSMIC-313, the phase 3 pivotal trial of cabozantinib, nivolumab and ipilimumab; and extended follow-up results from a non-clear cell renal cell carcinoma (RCC) cohort of COSMIC-021, the ongoing phase 1b trial of cabozantinib in combination with atezolizumab.

Cabozantinib Data Presentations at the 2023 ASCO Annual Meeting. In June 2023, cabozantinib will be the subject of 22 presentations at this year’s ASCO Annual Meeting, which is being held from June 2-6 in Chicago. Notable presentations will include results from the CONTACT-03 phase 3 trial evaluating the combination of cabozantinib and atezolizumab vs. cabozantinib alone in metastatic RCC patients who have progressed following treatment with an immune checkpoint inhibitor therapy, and three-year quality-of-life follow-up data from CheckMate -9ER.

Corporate Updates

Announcement of Key Priorities and Anticipated Milestones for 2023. In January 2023, Exelixis announced its key priorities and anticipated milestones for 2023, including: pivotal data readouts from the ongoing phase 3 studies evaluating the combination of cabozantinib with atezolizumab in patients with forms of metastatic castration-resistant prostate cancer (CONTACT-02) and RCC (CONTACT-03), the latter of which has subsequently occurred, and the next overall survival (OS) analysis from the phase 3 COSMIC-313 pivotal study for cabozantinib; expansion of the pivotal development program for zanzalintinib with multiple new phase 3 pivotal trial initiations; acceleration of the XB002 clinical program into full development by year-end; advancement of the XL102 QUARTZ-101 phase 1 study into the tumor-specific cohort-expansion stage and in planned combination cohorts; in collaboration with partner Cybrexa, progression of the phase 1 clinical study for CBX-12, including dose-expansion cohorts; expected filing of an Investigational New Drug application (IND) for ADU-1805 with the U.S. Food and Drug Administration (FDA) in the first quarter of 2023 by partner Sairopa B.V. (Sairopa), which has subsequently occurred; advancement of development candidates (DCs) XB010, XB014 and XB628 toward IND filings; and progress up to five new DCs into preclinical development across biotherapeutics and small molecules. Exelixis presented the details of its key priorities and anticipated milestones at the 41st Annual J.P. Morgan Healthcare Conference.

Cabozantinib Abbreviated New Drug Application (ANDA) Litigation Against MSN Pharmaceuticals, Inc. (MSN). In January 2023, the U.S. District Court for the District of Delaware (the Delaware District Court) ruled in Exelixis’ favor in the ANDA lawsuit against MSN (MSN I), rejecting MSN’s challenge to the cabozantinib compound patent (U.S. Patent No. 7,759,473). Additionally, the District Court ruled that MSN’s proposed ANDA product does not infringe Exelixis’ N-2 polymorph patent (U.S. Patent No. 8,877,776), expiring in October 2030. The decision in MSN I does not address the validity of the ‘776 patent, which was not contested by MSN, and the Delaware District Court entered judgment that any final FDA approval of MSN’s ANDA shall not be a date earlier than August 14, 2026, the expiration date of the ‘473 patent. In addition, this ruling in MSN I does not impact Exelixis’ separate and ongoing suit against MSN (MSN II) concerning four different Orange Book-listed patents related to cabozantinib, which expire between January 15, 2030, and February 10, 2032. A bench trial in MSN II is scheduled to begin in October 2023 in the U.S. District Court for the District of Delaware.

Announcement of $550 Million Share Repurchase Program. In March, Exelixis announced that the company’s Board of Directors authorized the repurchase of up to $550 million of the company’s common stock before the end of 2023. Share repurchases under the program may be made from time to time through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination of such methods. The timing and amount of any share repurchases under the share repurchase program will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of Exelixis’ common stock and general market conditions.

Pipeline Highlights

Exelixis and Sairopa Announce FDA Clearance of IND for ADU-1805 in Patients with Advanced Solid Tumors. In February, Exelixis and Sairopa announced FDA clearance of Sairopa’s IND to evaluate the safety and pharmacokinetics in a Phase 1 clinical trial of ADU-1805 in adults with advanced solid tumors, which has since been initiated. As a monoclonal antibody active against all human alleles of SIRPα, ADU-1805 has the potential to address a broader patient population than other SIRPα-directed therapies. By blocking SIRPα, a significant immune-suppressive component of the tumor microenvironment, ADU-1805 has the potential to improve the immune system’s ability to attack tumors. Under the terms of the clinical development and option agreement announced in November 2022, Exelixis has the option to obtain an exclusive, worldwide license to develop and commercialize ADU-1805 and other anti-SIRPα antibodies upon review of data from prespecified phase 1 clinical studies to be completed by Sairopa during the option period. This IND clearance triggered a $35.0 million milestone payment to Sairopa, paid in the first quarter of 2023.

Basis of Presentation

Exelixis has adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December 31st. For convenience, references in this press release as of and for the fiscal period ended April 1, 2022 is indicated as being as of and for the period ended March 31, 2022.

Conference Call and Webcast

Exelixis management will discuss the company’s financial results for the first quarter of 2023 and provide a general business update during a conference call beginning at 5:00 p.m. ET / 2:00 p.m. PT today, Tuesday, May 9, 2023.

To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.exelixis.com for one year.

About Exelixis

Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by bi-coastal centers of discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit www.exelixis.com, follow @ExelixisInc on Twitter, like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to: Exelixis’ research and development expectations for 2023, including initiating additional pivotal studies for zanzalintinib and, by year-end, accelerating XB002 into full development; Exelixis’ expectation that updated phase 1 data for CBX-12 will be presented at the ASCO Annual Meeting in June 2023; Exelixis’ plan to repurchase up to $550 million of its common stock before the end of 2023 as part of its commitment to deliver value to shareholders; Exelixis’ 2023 financial guidance; planned data presentations for cabozantinib at the 2023 ASCO Annual Meeting; Exelixis’ additional key priorities and anticipated milestones for 2023, including issuing pivotal data readouts from CONTACT-02 and the next OS analysis from COSMIC-313, advancing the XL102 QUARTZ-101 phase 1 study into the tumor-specific cohort-expansion stage and in planned combination cohorts, progressing the phase 1 clinical study for CBX-12 with dose-expansion cohorts, advancing of DCs XB010, XB014 and XB628 toward IND filings, and progressing up to five new DCs into preclinical development across biotherapeutics and small molecules; Exelixis’ expectation that the bench trial in MSN II will begin in October 2023 as scheduled; the clinical and therapeutic potential of ADU-1805, including its potential to improve the immune system’s ability to attack tumors, and Exelixis’ belief that ADU-1805 may address a broader patient population than other SIRPα-directed therapies; and Exelixis’ scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis’ current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the degree of market acceptance of CABOMETYX and other Exelixis products in the indications for which they are approved and in the territories where they are approved, and Exelixis’ and its partners’ ability to obtain or maintain coverage and reimbursement for these products; the effectiveness of CABOMETYX and other Exelixis products in comparison to competing products; the level of costs associated with Exelixis’ commercialization, research and development, in-licensing or acquisition of product candidates, and other activities; Exelixis’ ability to maintain and scale adequate sales, marketing, market access and product distribution capabilities for its products or to enter into and maintain agreements with third parties to do so; the availability of data at the referenced times; the potential failure of cabozantinib, zanzalintinib and other Exelixis product candidates, both alone and in combination with other therapies, to demonstrate safety and/or efficacy in clinical testing; uncertainties inherent in the drug discovery and product development process; Exelixis’ dependence on its relationships with its collaboration partners, including their pursuit of regulatory approvals for partnered compounds in new indications, their adherence to their obligations under relevant collaboration agreements and the level of their investment in the resources necessary to complete clinical trials or successfully commercialize partnered compounds in the territories where they are approved; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis’ continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating cabozantinib and other Exelixis product candidates; Exelixis’ dependence on third-party vendors for the development, manufacture and supply of its products and product candidates; Exelixis’ ability to protect its intellectual property rights; market competition, including the potential for competitors to obtain approval for generic versions of Exelixis’ marketed products; changes in economic and business conditions, including as a result of the COVID-19 pandemic and other global events; and other factors discussed under the caption “Risk Factors” in Exelixis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 7, 2023, and in Exelixis’ future filings with the SEC, including, without limitation, Exelixis’ Quarterly Report on Form 10-Q expected to be filed with the SEC on May 9, 2023. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law.

Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered trademarks of Exelixis, Inc.

 

EXELIXIS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share amounts)

(unaudited)

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

Revenues:

 

 

 

Net product revenues

$

363,400

 

 

$

310,298

License revenues

 

38,292

 

 

 

32,067

Collaboration services revenues

 

7,096

 

 

 

13,615

Total revenues

 

408,788

 

 

 

355,980

Operating expenses:

 

 

 

Cost of goods sold

 

14,315

 

 

 

13,203

Research and development

 

234,246

 

 

 

156,671

Selling, general and administrative

 

131,397

 

 

 

102,863

Total operating expenses

 

379,958

 

 

 

272,737

Income from operations

 

28,830

 

 

 

83,243

Interest income

 

19,502

 

 

 

1,822

Other income (expense), net

 

(54

)

 

 

164

Income before income taxes

 

48,278

 

 

 

85,229

Provision for income taxes

 

8,250

 

 

 

16,656

Net income

$

40,028

 

 

$

68,573

Net income per share:

 

 

 

Basic

$

0.12

 

 

$

0.21

Diluted

$

0.12

 

 

$

0.21

Weighted-average common shares outstanding:

 

 

 

Basic

 

324,420

 

 

 

319,582

Diluted

 

326,279

 

 

 

323,289

 

EXELIXIS, INC.

RECONCILIATION OF GAAP NET INCOME TO NON-GAAP NET INCOME

(in thousands, except per share amounts)

(unaudited)

 

Three Months Ended March 31,

 

 

2023

 

 

 

2022

 

GAAP net income

$

40,028

 

 

$

68,573

 

Adjustments:

 

 

 

Stock-based compensation – research and development expenses (1)

 

3,252

 

 

 

8,899

 

Stock-based compensation – selling, general and administrative expenses (1)

 

13,409

 

 

 

10,860

 

Income tax effect of the above adjustments

 

(3,861

)

 

 

(4,439

)

Non-GAAP net income

$

52,828

 

 

$

83,893

 

GAAP net income per share:

 

 

 

Basic

$

0.12

 

 

$

0.21

 

Diluted

$

0.12

 

 

$

0.21

 

Non-GAAP net income per share:

 

 

 

Basic

$

0.16

 

 

$

0.26

 

Diluted

$

0.16

 

 

$

0.26

 

Weighted-average common shares outstanding:

 

 

 

Basic

 

324,420

 

 

 

319,582

 

Diluted

 

326,279

 

 

 

323,289

 

____________________

(1)

Non-cash stock-based compensation expense used for GAAP reporting in accordance with Accounting Standards Codification Topic 718, Compensation—Stock Compensation.

 

Chris Senner

Chief Financial Officer

Exelixis, Inc.

650-837-7240

[email protected]

Susan Hubbard

EVP, Public Affairs & Investor Relations

Exelixis, Inc.

650-837-8194

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo
Logo

Leading South African Fintech Lesaka Technologies Completes Turnaround as it Champions Financial Inclusion Across Informal Markets

Leading South African Fintech Lesaka Technologies Completes Turnaround as it Champions Financial Inclusion Across Informal Markets

JOHANNESBURG, South Africa–(BUSINESS WIRE)–
Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released its results for the third quarter ended March 31, 2023 (“Q3 2023”) as the turnaround in the Group’s Consumer Division gathers momentum and the Merchant Division continues to outperform.

Performance highlights for Q3 2023:

  • Revenue of R2.4 billion, compared to R549.8 million in Q3 2022, an increase of 337% due to the inclusion and continued outperformance of the Connect Group and momentum in the successful turnaround of the Consumer Division.

  • Net loss attributable to Lesaka of R104.4 million, compared to R51.9 million in Q3 2022. Operating income (loss) before PPA amortization and net interest, a non-GAAP measure and reconciled below, was income of R34.0 million, compared to a loss R146.8 million in Q3 2022, and excludes amortization of acquired intangible assets R67.3 million, compared with R0.3 million in Q3 2022.

  • Adjusted EBITDA of R137.1 million, a 221% improvement compared to the Q3 2022 loss of R112.7 million.

  • Continued operating improvement demonstrated by further narrowing the operating loss to R33.2 million, representing an 77%(1) improvement from an operating loss of R147.1 million reported for Q3 2022.

  • Continued outperformance from the Merchant Division, delivering Adjusted EBITDA of R148.7 million.

  • Successful turnaround of the Consumer Division delivering Adjusted EBITDA of R29.6 million, compared to a loss of R13.5 million in Q3 2022.

  • Positive net cash generated by operating activities of R133 million, compared to an outflow of R81.3 million in Q3 2022.

Note 1 – before reorganisation costs of R91.4 million in Q3 2022

Lesaka Technologies has leveraged disruptive technologies to build a unique fintech platform which meets the needs of both merchants and consumers operating in informal and formal markets. More than 72,000 merchants use the Group’s cash management solutions, bill payment technologies, value-added services, business funding and card-acquiring solutions and 1.3 million consumers access Lesaka’s unsecured credit, transactional banking and micro-insurance products and services.

Lesaka’s strong third quarter results were driven by the transformational acquisition and outperformance of the Connect Group in the Merchant Division and the successful turnaround of the Group’s Consumer Division, despite the persistently challenging economic environment.

The Merchant Division continues to exceed expectations and grow across all products. A key highlight of the quarter was the performance of the informal market business, Kazang, which delivered the best quarter in the business’ history.

Lincoln Mali CEO Lesaka Southern Africa who has been driving the turnaround in the consumer business commented: “We work hard to add value to the lives of grant beneficiaries by understanding their needs and creating relevant and affordable financial products and services. We have been largely focused on turning the consumer business around as quickly as possible and now that we have achieved EBITDA profitability we can focus all our efforts on growth.”

Lesaka Group CEO Chris Meyer added “As a result of our improved trading, cash flow and our ability to deliver against what we have promised, our funders have, in a show of confidence, extended and increased our facilities providing us with flexibility and access to resources to execute on our growth plans. Q3 represents another quarter of growth and transformation. We are excited by the Merchant Division’s outperformance and another quarter of continued improvement and profitability in the Consumer Division where we are moving strongly on to the front foot.”

The full SENS announcement can be seen here.

Full release and webcast details at https://ir.lesakatech.com/.

The discussion of our consolidated overall results of operations is based on amounts as reflected in our unaudited condensed consolidated financial statements which are prepared in accordance with U.S. GAAP. We analyze our results of operations both in U.S. dollars, as presented in the unaudited condensed consolidated financial statements, and supplementally in ZAR, because ZAR is the functional currency of the entities which contribute the majority of our revenue and is the currency in which the majority of our transactions are initially incurred and measured. Due to the significant impact of currency fluctuations between the U.S. dollar and the ZAR on our reported results and because we use the U.S. dollar as our reporting currency, we believe that the supplemental presentation of our results of operations in ZAR is useful to investors to understand the changes in the underlying trends of our business.

Use of Non-GAAP Measures

U.S. securities laws require that when we publish any non-GAAP measures, we disclose the reason for using these non-GAAP measures and provide reconciliations to the most directly comparable GAAP measures. The presentation of EBITDA, Group Adjusted EBITDA, Operating income (loss) before PPA amortization and net interest, fundamental net (loss) income and fundamental (loss) earnings per share and headline (loss) earnings per share are non-GAAP measures.

Attached is the reconciliation between our GAAP measure and our non-GAAP measures.

Q3 – ended 31 March

FY23 Q3

FY22 Q3

FY23 Q3

FY22 Q3

 

ZAR’000

ZAR’000

$’000

$’000

Average exchange rate for conversion from ZAR to $

17.93

 

15.61

 

17.93

 

15.61

 

 

 

 

 

 

Net loss attributable to Lesaka (GAAP)

(104,363

)

(51,940

)

(5,820

)

(3,327

)

Earnings from equity-accounted investments

(305

)

 

(17

)

 

Income tax (benefit) expense

(15,422

)

7,338

 

(860

)

470

 

Net loss before income tax (benefit) expense

(120,090

)

(44,602

)

(6,697

)

(2,857

)

Interest expense

89,372

 

10,788

 

4,984

 

691

 

Interest income

(8,410

)

(11,881

)

(469

)

(761

)

PPA amortization (Amortization of acquired intangible assets)

67,269

 

256

 

3,789

 

15

 

Other items, comprising:

5,900

 

(101,384

)

329

 

(6,494

)

Loss on disposal of equity accounted investments

5,900

 

5,402

 

329

 

346

 

Gain on disposal of equity securities

 

(11,241

)

 

(720

)

Gain related to fair value adjustment to currency options

 

(95,545

)

 

(6,120

)

Operating income (loss) before PPA amortization and net interest (Non-GAAP)

34,041

 

(146,823

)

1,936

 

(9,406

)

PPA amortization (Amortization of acquired intangible assets)

(67,269

)

(256

)

(3,789

)

(15

)

Operating loss

(33,228

)

(147,079

)

(1,853

)

(9,421

)

Depreciation and amortization

107,143

 

7,228

 

5,975

 

463

 

Operating loss before depreciation and amortization (Non-GAAP)

73,915

 

(139,851

)

4,122

 

(8,958

)

Adjusted for:

 

 

 

 

Stock-based compensation

29,480

 

9,586

 

1,644

 

614

 

Lease adjustments

12,481

 

13,895

 

696

 

890

 

Once-off items

21,231

 

3,669

 

1,184

 

235

 

Group Adjusted EBITDA (Non-GAAP)

137,107

 

(112,701

)

7,646

 

(7,219

)

 

Investor Relations Contact:

Phillipe Welthagen

Email: [email protected]

Mobile: +27 84 512 5393

FNK IR:

Rob Fink / Matt Chesler, CFA

Email: [email protected]

Media Relations Contact:

Janine Bester Gertzen

Email: [email protected]

KEYWORDS: Africa South Africa

INDUSTRY KEYWORDS: Technology Insurance Payments Finance Security Fintech Banking Professional Services Software

MEDIA:

Logo
Logo